Document:

Exhibit 10.1

Exhibit 10.1

Execution Copy

ASSET PURCHASE AGREEMENT

among

BENEN TRADING LTD.,

CORTEX BIOCHEM, INC.

and

THE SHAREHOLDERS OF CORTEX BIOCHEM, INC.

September 4, 2007

 

 

 

Table of Contents

	 	 	 	 	 
	ARTICLE I SALE OF ASSETS AND TERMS OF PAYMENT
	 	 	1	 
	 
	 	 	 	 
	1.01 Assets Being Sold (the “Purchased Assets”)
	 	 	1	 
	1.02 Retained Assets
	 	 	3	 
	1.03 Assumed Liabilities
	 	 	3	 
	1.04 Purchase Price
	 	 	3	 
	1.05 Allocation of the Purchase Price
	 	 	4	 
	1.06 Absolute Sale
	 	 	4	 
	1.07 Other Contracts
	 	 	4	 
	1.08 Bulk Sales Laws
	 	 	4	 
	 
	 	 	 	 
	ARTICLE II RELATED AGREEMENTS
	 	 	4	 
	 
	 	 	 	 
	2.01 Bill of Sale
	 	 	4	 
	2.02 Assignment of Intellectual Property Right
	 	 	5	 
	2.03 Transition Services Agreement
	 	 	5	 
	 
	 	 	 	 
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER
	 	 	5	 
	 
	 	 	 	 
	3.01 Organization and Good Standing
	 	 	5	 
	3.02 Authorization, Compliance with Other Instruments and Law
	 	 	5	 
	3.03 Financial Statements
	 	 	6	 
	3.04 Operation of Seller in the Ordinary Course
	 	 	6	 
	3.05 Tax Matters
	 	 	7	 
	3.06 Material Contracts and Commitments
	 	 	8	 
	3.07 Licenses, Permits and Authorizations
	 	 	8	 
	3.08 Title to Purchased Assets
	 	 	8	 
	3.09 Transferred Intellectual Property
	 	 	8	 
	3.10 Employee Benefit Plans
	 	 	9	 
	3.11 Litigation and Other Claims
	 	 	10	 
	3.12 No Material Adverse Change
	 	 	10	 
	3.13 Sufficiency of Purchased Assets
	 	 	10	 
	3.14 Compliance with Laws
	 	 	10	 
	3.15 Insurance
	 	 	11	 
	3.16 Accounts Receivable; Inventory
	 	 	11	 
	3.17 Labor Matters
	 	 	12	 
	3.18 Condition of Purchased Assets
	 	 	12	 
	3.19 Environmental Matters
	 	 	12	 
	3.20 Absence of Certain Payments
	 	 	14	 
	3.21 Full Disclosure
	 	 	14	 
	 
	 	 	 	 
	ARTICLE IV REPRESENTATIONS, WARRANTIES AND COVENANTS OF BUYER
	 	 	14	 

 

-ii-

 

	 	 	 	 	 
	4.01 Organization
	 	 	14	 
	4.02 Due Authorization
	 	 	14	 
	 
	 	 	 	 
	ARTICLE V COVENANTS PENDING CLOSING AND OTHER AGREEMENTS
	 	 	15	 
	 
	 	 	 	 
	5.01 Conduct of Business of Seller Prior to the Closing
	 	 	15	 
	5.02 Access to Information
	 	 	16	 
	5.03 Consents
	 	 	16	 
	5.04 Public Announcements
	 	 	16	 
	5.05 Confidentiality
	 	 	16	 
	5.06 Related Agreements
	 	 	17	 
	5.07 No-Shop
	 	 	17	 
	5.08 Website
	 	 	17	 
	5.09 Licenses
	 	 	18	 
	5.10 Consulting Services
	 	 	18	 
	 
	 	 	 	 
	ARTICLE VI CLOSING CONDITIONS
	 	 	19	 
	 
	 	 	 	 
	6.01 Conditions to Each Party’s Obligations to Effect the
Transactions Contemplated Hereby
	 	 	19	 
	6.02 Conditions to the Obligations of Seller to Effect the
Transactions Contemplated Hereby
	 	 	19	 
	6.03 Conditions to the Obligations of Buyer to Effect the
Transactions Contemplated Hereby
	 	 	19	 
	 
	 	 	 	 
	ARTICLE VII THE CLOSING
	 	 	20	 
	 
	 	 	 	 
	7.01 Time and Place of Closing
	 	 	20	 
	7.02 Closing
	 	 	21	 
	 
	 	 	 	 
	ARTICLE VIII EMPLOYMENT, WORKERS’ COMPENSATION AND PRODUCT
LIABILITY RESPONSIBILITY
	 	 	21	 
	 
	 	 	 	 
	8.01 Employment; Workers’ Compensation
	 	 	21	 
	8.02 Product Liability and Warranty Claims
	 	 	21	 
	8.03 Responsibility for Prior Claims
	 	 	21	 
	 
	 	 	 	 
	ARTICLE IX POST-CLOSING COVENANTS
	 	 	21	 
	 
	 	 	 	 
	9.01 Further Assurances
	 	 	21	 
	9.02 Commissions and Fees
	 	 	22	 
	9.03 Sales, Transfer and Use Taxes
	 	 	22	 
	9.04 Nondisclosure; Noncompetition
	 	 	22	 
	9.05 Indemnification
	 	 	23	 
	9.06 Defense of Claims
	 	 	24	 
	9.07 Expenses
	 	 	26	 

 

-iii-

 

	 	 	 	 	 
	9.08 Settlement of Seller’s Obligations
	 	 	26	 
	 
	 	 	 	 
	ARTICLE X MISCELLANEOUS
	 	 	26	 
	 
	 	 	 	 
	10.01 Binding Effect
	 	 	26	 
	10.02 No Assignment
	 	 	26	 
	10.03 Counterparts
	 	 	26	 
	10.04 Governing Law
	 	 	26	 
	10.05 Suits in California
	 	 	26	 
	10.06 Survival
	 	 	27	 
	10.07 Notices
	 	 	27	 
	10.08 Amendment and Modification
	 	 	28	 
	10.09 Waiver of Compliance
	 	 	28	 
	10.10 Interpretation
	 	 	28	 
	10.11 Entire Agreement
	 	 	28	 
	10.12 Specific Performance
	 	 	29	 
	10.13 Severability of Covenants
	 	 	29	 
	 
	 	 	 	 
	ARTICLE XI TERMINATION AND ABANDONMENT
	 	 	29	 
	 
	 	 	 	 
	11.01 Termination
	 	 	29	 
	11.02 Procedure and Effect of Termination
	 	 	30	 

 

-iv-

 

SCHEDULES

	 	 	 
	Schedule	 	Description
	1.01(a)

	 	Fixed Assets
	1.01(b)

	 	Inventories
	1.01(c)

	 	Contracts and Commitments
	1.01(d)

	 	Accounts Receivable
	1.01(e)

	 	Proprietary Rights
	1.01(g)(i)

	 	Software used exclusively for Business
	1.01(g)(ii)

	 	Software used for Business and Magnetic Particle Business
	1.01(h)

	 	Governmental Licenses, Permits and Authorizations
	1.01(i)

	 	Credits and Prepaid Expenses
	1.03

	 	Assumed Liabilities
	1.05

	 	Allocation of the Purchase Price
	1.09

	 	Consignment Inventory
	2.04

	 	Persons signatory to Non-Competition Agreements
	3.02

	 	Authorization, Compliance with Other Instruments and Law
	3.05

	 	Tax Matters
	3.07

	 	Licenses, Permits and Authorizations
	3.08

	 	Title Exceptions
	3.10

	 	Employee Benefit Plans
	3.11

	 	Litigation and Other Claims
	3.13

	 	Assets Used for Business Not Sold
	3.14

	 	FDA Approvals and Notices
	3.15

	 	Insurance
	3.16

	 	Inventory; Accounts Receivable
	3.17

	 	Labor Matters
	3.19

	 	Environmental Matters
	9.02

	 	Commissions and Fees

 

-v-

 

EXHIBITS

	 	 	 
	Exhibit	 	Description
	 	 	 

	A	 	Bill of Sale and Assignment and Assumption Agreement

	 	 	 

	B	 	Assignment of Intellectual Property

	 	 	 

	C	 	Transition Services Agreement

 

-vi-

 

ASSET PURCHASE AGREEMENT

THIS
AGREEMENT (the “Agreement”) is made as of August _____, 2007 among BENEN TRADING
LTD., an Irish limited company (“Buyer”) CORTEX BIOCHEM, INC., a California corporation
(“Seller”), and DR. MATT POURFARZANEH, LEONARD I. KARP, EDWARD J. RITELLI, JR., (the
“Founding Shareholders”), RAY POURFARZANEH and DR. DOKHI NARGESSI, the sole shareholders of
Seller (together, with the Founding Shareholders, the “Shareholders”).

SUMMARY OF TRANSACTION

Seller is engaged, among other business lines not be sold under this Agreement (such business
lines, collectively, the “Magnetic Particle Business”), in the business of selling purified
antigens, primary antibodies, secondary antibodies, including antibodies for infectious disease and
reporter gene research studies (the “Business”). Seller wishes to sell and Buyer wishes to
purchase all of the assets and to assume certain liabilities related to the Business of Seller.

ARTICLE I

SALE OF ASSETS AND TERMS OF PAYMENT

1.01 Assets Being Sold (the “Purchased Assets”). Seller agrees to sell and Buyer
agrees to purchase, at the Closing (as defined in Section 7.01 hereof), all of the assets
of Seller related to the Business as they shall exist on the Closing Date (as defined in
Section 7.01 hereof), except for the Retained Assets (as defined in Section 1.02
hereof), including without limitation the following assets:

(a) Fixed Assets. All the fixed assets, including equipment, computers,
fixtures, fittings, furniture and machinery, of Seller related exclusively to the Business
which are listed in Schedule 1.01(a) hereto, which shall be updated to include all
similar assets of Seller acquired hereafter immediately prior to the Closing;

(b) Inventories. All inventories owned by Seller of any kind related to the
Business, including, but not limited to, finished goods, work-in-process, supplies and raw
materials listed on Schedule 1.01(b), which shall be updated to include all similar
assets of Seller acquired hereafter immediately prior to the Closing;

(c) Contracts and Commitments. All of the rights, title and interest of Seller
in, to and under all pending and executory contracts, agreements, commitments and
understandings of Seller related exclusively to the Business, including, without limitation,
those with respect to (x) the purchase of materials, supplies or services, (y) the sale of
products, and (z) the Material Contracts as defined in Section 3.06, which Material
Contracts are listed in Schedule 1.01(c) hereto;

 

 

 

(d) Accounts Receivable. All accounts receivable related to the Business as
set forth on Schedule 1.01(d), which shall be updated to include the then current
accounts receivable immediately prior to the Closing;

(e) Proprietary Rights.

(i) Patents, Trademarks and Related Assets. All domain names, Internet web
sites (including, without limitation, www.cortex-biochem.com, which web site will be
modified pursuant to Section 5.08) their contents, software and goodwill appurtenant
thereto, and applications therefor, copyrights, tradenames (but not including “Cortex
Biochem,” for which Seller grants to Buyer a license pursuant to Section 5.09),
brand names and licenses (“Proprietary Rights”) of Seller related exclusively to the
Business, including those listed in Schedule 1.01(d) hereto;

(ii) Technical Know-how. All proprietary and other technical information and
technology (“Technical Know-how”) owned by Seller related exclusively to the
Business (including research and development in progress), including inventions and
discoveries, data sheets, protocols, improvements, processes, know-how, formulae, drawings,
specifications, production data, trade secrets, plans, files, notebooks and other records
and documents pertaining to research and development;

(iii) Licenses. All right, title and interest related to the Business of
Seller in, to and under any licenses of any Proprietary Rights or Technical Know-how owned
by any third party; and

(iv) Related Agreements. All secrecy or other agreements with others,
including employees, relating to disclosure, assignment or patenting of any Proprietary
Rights or Technical Know-how, to the extent that such agreements relate to the Business;

(f) Books and Records. All materials, including all books and records, sales
and credit records, marketing, advertising and sales material, literature, catalogues and
other publications, customer lists, supplier lists, financial records and personnel and
payroll records of Seller related exclusively to the Business, but excluding the corporate
books and records of the Seller, in electronic format, if available, otherwise in printed
form;

(g) Software. All software being used exclusively in the Business set forth on
Schedule 1.01(g)(i) (for software used for the Business and the Magnetic Particle
Business, which is set forth on Schedule 1.01(g)(ii), Seller grants a license
pursuant to Section 5.09). 

(h) Governmental Licenses, Permits and Authorizations. To the extent
assignable, all governmental licenses, permits and authorizations related to the Business,
if any, a complete list of which is set forth in Schedule 1.01(h) hereto;

 

-2-

 

(i) Credits and Prepaid Expenses. To the extent assignable, all of Seller’s
credits, prepaid expenses and other current assets related to the Business listed in
Schedule 1.01(i);

(j) Intangible Assets. The Business as a going concern and the goodwill
thereof; and

(k) Other Assets. All other assets, properties, and rights of every kind and
nature owned or held by Seller related exclusively to the Business or in which Seller has an
interest related exclusively to Business on the Closing Date, known or unknown, fixed or
unfixed, accrued, absolute, contingent or otherwise, whether or not specifically referred to
in this Agreement, other than the Retained Assets.

1.02 Retained Assets. Notwithstanding the foregoing, the Purchased Assets shall not
include any cash held by Seller or any assets of the Magnetic Particle Business all of which shall
be retained by Seller (the “Retained Assets”).

1.03 Assumed Liabilities.

Buyer assumes (a) Seller’s accounts payable as of the Closing Date for raw materials and
finished goods delivered by third party suppliers, related to the Business (purchased pursuant to
Section 1.01(b)), which accounts payable are set forth in Schedule 1.03, to be
provided one business day before Closing and (b) the liabilities and obligations under the
contracts purchased and assumed by Buyer pursuant to Section 1.01(c) above, but only to the extent
such liabilities and obligations arise from the conduct of business after the Closing (the
“Assumed Liabilities”). Other than the Assumed Liabilities Seller shall retain all
liabilities of any nature whatsoever, including without limitation, any liabilities or obligations
related to the operation of the Business or the Magnetic Particle Business, or any of the Seller’s
assets, employees, properties, contracts and agreements (collectively the “Retained
Liabilities”). Seller and the Shareholders hereby jointly and severally agree to indemnify and
hold harmless Buyer with respect to any of the Retained Liabilities in the manner provided
in Section 9.05(a) hereof.

1.04 Purchase Price.

Buyer, in consideration for the purchase of the Purchased Assets being sold pursuant to this
Agreement, agrees to pay and deliver to Seller, at the Closing, cash in the amount of US $2,800,000
in immediately available Federal Funds by wire transfer to the bank account of Seller designated by
Seller in writing not less than two days before the Closing (the “Base Purchase Price”).
In addition, Buyer will also pay, at the Closing, cash in an amount equal to 80% of (i) the
accounts receivable purchased by the Buyer under Section 1.01(d) (to the extent such
accounts receivable are collectible, as determined in good faith among the parties prior to
Closing), less (ii) the accounts payable assumed by Buyer as Assumed Liabilities under Section
1.03 (the “Additional Purchase Price”). The Base Purchase Price and the Additional
Purchase Price are collectively referred to as the “Purchase Price”.

 

-3-

 

1.05 Allocation of the Purchase Price. Seller and Buyer agree to allocate the
purchase price for the Purchased Assets in the manner set forth in Schedule 1.05 hereto,
which allocation the parties shall adhere to for the purposes of all Federal, state and local tax
returns filed by them subsequent to the Closing, including the determination by Seller of taxable
gain or loss on the sale of the Purchased Assets hereunder and the determination by Buyer of its
tax basis with respect to the Purchased Assets.

1.06 Absolute Sale. Seller agrees that the sale, conveyance, transfer and delivery of
the Purchased Assets to Buyer shall be free and clear of all title defects, liabilities,
obligations, liens, encumbrances, charges and claims of any kind, except for the title exceptions
listed in Schedule 3.08 hereto.

1.07 Other Contracts. This Agreement shall not constitute an agreement to assign or
sublicense, as the case may be, any contracts, leases, licenses, agreements or arrangements (for
purposes of this Section 1.07 collectively called “contracts”) if such attempted
assignment or sublicense, without the consent of the other party thereto, is not permitted as a
matter of law or in accordance with the terms of such contracts or would constitute a breach of
such contracts or would in any way impair the rights of Seller or Buyer thereunder. Seller will
use its best efforts to obtain, or will assist Buyer to obtain, such consents as may be necessary
or appropriate to vest in Buyer all of Seller’s right, title and interest in all such contracts.
If such consent is not obtained or if an assignment, attempted assignment or sublicense is not so
permitted or would be ineffective or would impair Buyer’s rights thereunder, Seller will cooperate
with Buyer in any reasonable arrangement designed to provide for Buyer the benefits under any such
contracts.

1.08 Bulk Sales Laws. Seller and Buyer hereby waive compliance with the provisions of
any applicable bulk sales laws; provided, however, that Seller and Shareholder
agrees to pay and discharge when due or to contest or litigate all claims of creditors which are
asserted against Buyer or the Purchased Assets by reason of such noncompliance, to indemnify,
defend and hold harmless Buyer from and against any and all such claims (other than Assumed
Liabilities) in the manner provided in Section 9.05(a) hereof, and to take promptly all
necessary action to remove any lien or encumbrance which is placed on the Purchased Assets by
reason of such noncompliance.

ARTICLE II

RELATED AGREEMENTS

Simultaneously with the Closing hereunder the following agreements (the “Related
Agreements”) shall be executed and delivered:

2.01 Bill of Sale. Bill of Sale and Assignment and Assumption Agreement substantially
in the form attached as Exhibit A;

 

-4-

 

2.02 Assignment of Intellectual Property Right. Assignment Agreement for Intellectual
Property in the form of Exhibit B.

2.03 Transition Services Agreement. Transition Services Agreement between Buyer and
Seller in the form attached hereto as Exhibit C (the “Transition Services
Agreement”).

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller and Shareholders represent and warrant to, and covenant with, Buyer that as of the date
hereof and as of the Closing Date:

3.01 Organization and Good Standing. Seller is a corporation duly organized, validly
existing and in good standing under the laws of the State of California, and has the corporate
power and authority to own and operate its properties and assets (including the Purchased Assets)
and to conduct the Business as it is now being conducted. Seller is duly qualified to do business
in all other jurisdictions in which Seller owns, leases or operates property or otherwise conducts
Seller’s business if the failure to be qualified would have a material adverse effect on Seller’s
ability to conduct business using the Purchased Assets.

3.02 Authorization, Compliance with Other Instruments and Law. Seller has full
corporate power and authority to enter into this Agreement and the other agreements and documents
to be executed and delivered by it at the Closing as contemplated hereby (collectively, the
“Closing Documents”), to consummate the transactions contemplated hereby and thereby and to
perform its obligations hereunder and thereunder. The execution, delivery and performance of this
Agreement and the Closing Documents and the consummation of the transactions contemplated hereby
and thereby have been duly authorized by all necessary corporate action on the part of the
shareholders and board of directors of Seller. This Agreement has been duly executed and delivered
by Seller and Shareholders, and is a valid and binding obligation of Seller and Shareholders
enforceable against Seller and Shareholders in accordance with its terms and the Closing Documents
will, when executed and delivered by Seller and Shareholders at Closing, constitute valid and
binding obligations of Seller and Shareholders enforceable against Seller and Shareholders in
accordance with their terms. The execution, delivery and performance of this Agreement and the
Closing Documents will not (i) conflict with or result in a breach or violation of any provision of
the Articles of Incorporation or By-Laws of Seller or of any order, writ, injunction, judgment,
decree, law, statute, rule or regulation to which either of the Seller or Shareholders is a party
or by which Seller, Shareholders or the Purchased Assets may be bound or affected; or (ii) except
as set forth in Schedule 3.02, result in a default (or give rise to any right of
termination, cancellation or acceleration) or result in the creation of any lien, encumbrance,
security agreement, charge, pledge, equity or other claim or right of any person in or to the
Purchased Assets under the terms, conditions or provisions of any note, bond, mortgage, indenture,
license, agreement or other instrument or obligation to which either of the Seller or Shareholders
is a party or by which the Seller, Shareholders or the Purchased Assets may be bound. All
necessary authorizations of the transactions contemplated by this Agreement required to be obtained
by the Seller or Shareholders from any Federal, state, local or foreign

 

-5-

 

government or agency shall have been obtained prior to the Closing, and any filings,
notifications or disclosures required by law or regulation of any such government or agency shall
have been made in such form as is acceptable as filed. Buyer shall cooperate with Seller and
Shareholders with respect to the aforesaid filings, notifications or disclosures to the extent
necessary to obtain said authorizations. Seller will deliver to Buyer at the Closing true and
complete copies of all resolutions of its shareholders, if required, and board of directors by
which the execution, delivery and performance of this Agreement and the Closing Documents and the
consummation of the transactions contemplated hereby and thereby were authorized, certified by its
respective Secretary or Assistant Secretary as of the Closing Date.

3.03 Financial Statements.

Seller has previously furnished to Buyer true and correct copies of (i) the unaudited balance
sheets of Seller as of December 31, 2006 and July 31, 2007; and (ii) the unaudited income
statements of Seller which income statements separately list the Business and the Magnetic Particle
Business for the fiscal years ended December 31, 2006 and the seven months ended July 31, 2007
(collectively, the “Financial Statements”). The balance sheets included in the Financial
Statements (including the related notes thereto) are true, complete and correct and present fairly
the financial position of Seller as of their respective dates, and the related income statements
included in the Financial Statements are true, complete and correct and present fairly the results
of operations of Seller for the periods then ended, all in conformity with United States GAAP
applied on a consistent basis.

3.04 Operation of Seller in the Ordinary Course. (a) Since the close of
business on December 31, 2006, Seller’s Business has been operated, and through the Closing
Date will have been operated, in the ordinary course, except to the extent that Buyer has
otherwise agreed (or may prior to the Closing Date otherwise agree) in writing or as is
expressly contemplated by this Agreement. From the date hereof until the Closing Date,
Seller shall continue to use its best efforts to preserve the goodwill of Seller’s Business
and its relationship with employees, customers and suppliers.

(b) In furtherance of the foregoing, since December 31, 2006, the Seller has not with
respect to the Business (i) incurred any obligations or liabilities, whether absolute,
accrued, contingent or other, other than obligations and liabilities incurred in the
ordinary course of business, (ii) mortgaged, pledged or subjected to any lien, lease,
security interest or other encumbrance (other than liens for taxes, assessments or other
governmental charges not yet due and payable, or presently payable without penalty or
interest) any of its assets, real or personal, tangible or intangible, (iii) acquired or
disposed of any assets or properties used in the operation of the Business, or entered into
any agreement for any such acquisition or disposition, except in the ordinary course of
business, (iv) forgiven or canceled any debts or claims other than in the ordinary course of
business or waived any rights of material value not previously accrued for, (v) granted any
rights or licenses under or to any of its patents, trademarks, trade names, copyrights,
domain names or other intellectual property rights, (vi) suffered any loss of, or material
adverse change in its relationship with, any supplier or customer or has knowledge that any
such supplier or customer intends any action which would constitute or lead to such a

 

-6-

 

loss or material adverse change, (vii) suffered any damage, destruction or loss
(whether or not covered by insurance) which has a material adverse effect on its business,
(viii) suffered any strike or other labor trouble which has had a material adverse effect on
its operations, (ix) terminated or made any substantial revision of, or engaged in any
renegotiation of, any material contract, (x) made any change in accounting principles or
methods or in classification, depreciation or amortization policies or rates, (xi) settled
any dispute involving payment by the Seller in excess of $10,000, (xii) made any loan or
advance in excess of $10,000 to any person or entity other than travel or expense advances
in accordance with its normal policies which have been accounted for or repaid and extension
of trade credit in accordance with its normal business practices, or (xiii) entered into any
material transaction other than in the ordinary course of business.

3.05 Tax Matters. Other than as disclosed on Schedule 3.05:

(a) Seller has: (i) timely filed all returns, declarations, reports, estimates, information
returns, and statements (“Returns”) required to be filed or sent by it in respect of any
“Taxes” (as defined in subsection (d) below) and all such Returns were complete and correct
in all material respects and (ii) timely and properly paid all Taxes required to be paid by it
through the date hereof (including any Taxes shown due on any Return).

(b) There are no liens for Taxes upon any of the Purchased Assets, except liens for Taxes not
yet due.

(c) No deficiency for any Taxes has been proposed, asserted or assessed against Seller that
has not been resolved and paid in full. No waiver, extension or comparable consent given by Seller
regarding the application of the statute of limitations with respect to any Taxes or Returns is
outstanding, nor is any request for any such waiver or consent pending. No Tax audit or other
administrative proceeding or court proceeding with regard to any Taxes or Returns is pending, nor
has there been any notice to Seller by any taxing authority regarding, or is any such tax audit or
other proceeding threatened with regard to, any Taxes or Returns. Seller does not expect the
assessment of any additional Taxes on Seller and is not aware of any unresolved questions, claims
or disputes concerning the liability for Taxes on Seller which would exceed the estimated reserves
therefor set forth in the Financial Statements. Seller is not nor has it ever been a party to any
tax sharing agreement with any person. As concerns the Purchased Assets, the liabilities assumed
by the Buyer and the Business, Seller has complied in all material respects with all applicable
laws relating to the collection or withholding of Taxes (such as sales Taxes or withholding of
Taxes from the wages of employees), and Seller has not been and is not liable for any Taxes for
failure to comply with such laws.

(d) For purposes of this Agreement, the terms “Tax” or “Taxes” means all
taxes, charges, fees, levies, or other assessments, including, without limitation, all net income,
gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license,
withholding, payroll, employment, social security, unemployment, excise, estimated, severance,
stamp, occupation, property, or other taxes, customs duties, fees, assessments, or charges of any
kind whatsoever, including, without limitation, all interest and penalties thereon, and additions
to tax or additional amounts imposed by any valid taxing authority upon Seller.

 

-7-

 

3.06 Material Contracts and Commitments. Schedule 1.01(c) hereto constitutes
a full and complete list, as of the date hereof, of all contracts and commitments of Seller related
to the Business involving aggregate rights or obligations of Seller in excess of $5,000 per
contract or which have a remaining term, as of the date hereof, of over six months in length of
obligation on the part of Seller (“Material Contracts”). Except as indicated on
Schedule 1.01(c), Seller is not in breach or violation of, or in default under any of the
Material Contracts; the execution of this Agreement and the consummation of the transactions
contemplated hereby will not constitute a default or breach under the Material Contracts; and,
except as specifically indicated in Schedule 1.01(c), the execution of this Agreement and
the consummation of the transactions contemplated hereby will not give rise to any consent
requirement under any of the Material Contracts. All of the contracts listed on Schedule
1.01(c) are in full force and effect and have not been modified or amended, except as set forth
on Schedule 1.01(c).

3.07 Licenses, Permits and Authorizations. Seller has obtained, and will as of the
Closing Date continue to have, all material approvals, authorizations, consents, licenses,
franchises, orders, certificates and other permits of, and has made and will have made on the
Closing Date all filings with, any governmental authority, whether foreign, Federal, state or
local, which are required for the ownership of the Purchased Assets or the conduct of Seller’s
Business as presently conducted. A complete list of all such approvals, authorizations, consents,
licenses, franchises, orders, certificates, permits and filings is included as Schedule
3.07 hereto.

3.08 Title to Purchased Assets. Seller has good title to the Purchased Assets and
shall at the Closing deliver to Buyer good title to the Purchased Assets free and clear of all
title defects, liabilities, obligations, liens, mortgages, security interests, encumbrances,
easements, claims or similar adverse interests of any kind or character except for the title
exceptions listed in Schedule 3.08 hereto. All leases pursuant to which Seller leases any
of the Purchased Assets are valid and binding in accordance with their respective terms. Seller is
not in breach or violation, or default under any agreement or lease, which breach, violation or
default might result in the creation of any mortgage, security interest, encumbrance, easement,
claim or similar adverse interest of any kind or character.

3.09 Transferred Intellectual Property. Except as set forth in Schedule
1.01(d), to the knowledge of Seller or Shareholders and only insofar as they relate to the
Business:

(a) Seller owns or has the right to use pursuant to license, sublicense, public domain,
agreement, or permission the following intellectual property (the “Transferred
Intellectual Property”): (i) all trademarks, service marks, trade dress, logos, trade
names, and corporate names, including all goodwill associated therewith, and all
applications registrations, and renewals in connection therewith, (ii) all trade secrets and
confidential business information (including protocols, ideas, research and development,
know-how, formulas, compositions, manufacturing and production processes and techniques,
technical data, designs, drawings, specifications, customer and supplier lists, pricing and
cost information, and business and marketing plans and proposals), (iii) all other
proprietary rights, and (iv) all copies and tangible embodiments thereof (in whatever form
or medium).

 

-8-

 

(b) Seller, its officers and Shareholders have (i) not knowingly interfered with,
infringed upon, misappropriated, or otherwise come into conflict with any intellectual
property rights of third parties, and (ii) never received any charge, complaint, claim,
demand, or notice alleging any such interference, infringement, misappropriation, or
violation, including any claim that Seller or Shareholders must license or refrain from
using any intellectual property rights of any third party, which might result in a material
adverse effect to the Business. To the knowledge of Seller or Shareholders, no third party
has interfered with, infringed upon, or misappropriated in any material respect any
intellectual property rights of Seller.

(c) Sellers does not have any (i) patents or pending patent application or application
for registration which Seller has made with respect to any of the Transferred Intellectual
Property, (ii) material license, agreement, or other permission which Seller has granted to
any third party with respect to any of the Transferred Intellectual Property outside the
ordinary course of business, or (iii) registered trade names or registered trademarks used
by Seller with respect to the Transferred Intellectual Property.

3.10 Employee Benefit Plans.

(a) For purposes of this Section 3.10, “Employee Plan” shall mean any “employee
benefit plan,” as defined in section 3(3) of the Employment Retirement Income Security Act
of 1974, as amended (“ERISA”), whether or not such plan is subject to any of the provisions
of ERISA, and any qualified or non-qualified current or deferred compensation, bonus,
incentive compensation, stock-based rights, option or appreciation plan, severance pay,
retirement, pension, supplemental pension, profit-sharing, stock bonus, salary continuation,
tuition assistance, dependent care assistance, legal assistance, vacation, fringe benefit,
group or individual health, medical, dental, vision, disability, life insurance or survivor
benefit or similar plan, policy or arrangement, which covers any employee, self-employed
individual or beneficiary of any employee or self-employed individual, whether active or
retired, of Seller, any predecessor of Seller, or any entity which, with Seller, is
considered to be part of a single employer under Section 414(b), (c), (m) or (o) of the
Code.

(b) No Employee Plan of Seller is a “defined benefit plan,” as defined in Section 3(35)
of ERISA and subject to Title IV of ERISA, or a “multi-employer plan,” as defined in Section
3(37) of ERISA, and Seller has not been obligated to make a contribution to any “defined
benefit plan” or “multi-employer plan” within the five year period preceding the date of
this Agreement.

(c) No “party in interest” as defined in section 3(14) of ERISA or “disqualified
person” as defined under Section 4975 of the Code has engaged in a “prohibited transaction,”
as defined in Section 406 of ERISA or Section 4975 of the Code, with respect to any Employee
Plan which could subject Buyer to liability, restitution or penalty under Section 409 or
502(i) of ERISA or Section 4975 of the Code.

(d) Seller is in material compliance with, and has administered each of its

 

-9-

 

Employee Plans in accordance with, the terms of such plan and the requirements of any
and all laws, orders, decrees and regulations, including but not limited to, ERISA and the
Consolidated Omnibus Budget Reconciliation Act of 1985, applicable to each such plan.

(e) There is no pending or, to the best of Seller’s or Shareholders’ knowledge,
threatened legal action, arbitration or other proceeding or investigation against Seller or
any Employee Plan with respect to any Employee Plan which could result in any penalty or
liability for Buyer, and there is no reasonable basis for any such legal action or
proceeding.

(f) No employer securities, employer real property or other employer property is
included in the assets of any Employee Plan.

3.11 Litigation and Other Claims. Except as described in Schedule 3.11, there
are no actions, suits, arbitration proceedings, claims or other proceedings arising out of or
related to the Business of the Seller pending or, to the knowledge of Seller or Shareholders,
threatened before any foreign, Federal, state, municipal or other court, department, commission,
arbitration panel, board, bureau, agency, body or instrumentality against Seller or affecting the
Purchased Assets at law or in equity. Seller and Shareholders are not a party to or subject to the
provisions of any order, writ, injunction, decree or judgment of any court or foreign, Federal,
state, municipal or other governmental or administrative body, department, commission, board,
bureau, securities exchange or other agency or instrumentality in connection with the ongoing
operations of Seller except as set forth in Schedule 3.11.

3.12 No Material Adverse Change. Since the close of business on the date of the
Financial Statements, there has been no material adverse change in the financial condition, or
results of operations of the Business of Seller.

3.13 Sufficiency of Purchased Assets. Except as set forth on Schedule 3.13,
the Purchased Assets have been sufficient for Seller to operate the Business as currently operated.
Seller is not a party to any contract which is necessary in any material respect to Seller’s
Business other than contracts which will be assigned to Buyer at the Closing hereunder.

3.14 Compliance with Laws.

(a) To Seller’s and Shareholders’ knowledge, neither the Purchased Assets nor the
operations of the Business, as conducted at the date hereof and as will be conducted through
the Closing Date, violate, in any material respect, any foreign, Federal, state or local
law, ordinance, rule or regulation.

(b) To Seller’s and Shareholders’ knowledge, Seller, as well as each of its
“establishments” and “relevant persons” (as such terms are defined under the Federal Food,
Drug and Cosmetic Act, 21 U.S.C. §§ 301 et. seq. (collectively the
“Regulated Group”), is currently in compliance in all material respects with all
regulatory requirements of the Federal Food and Drug Administration (the “FDA”),
including without limitation all registration, Good Manufacturing Practices, licensing and

 

-10-

 

recordkeeping requirements, to the extent applicable. To Seller’s and Shareholders’
knowledge, each member of the Regulated Group currently has all permits, licenses,
authorizations and approvals required by the FDA, all of which are listed on Schedule
3.14, and is in compliance with all conditions and terms of such permits, licenses,
authorizations and approvals. The transactions contemplated hereby will not conflict with
or result in any violation of such permits, licenses, authorizations and approvals, and any
notices to, or consents by, the FDA required in connection with such transactions (all of
which are listed on Schedule 3.14) have been obtained prior to the Closing
Date. Except as set forth on Schedule 3.14, no notice has been received, and no
review or investigation is pending, or to Seller’s or Shareholders’ knowledge, threatened
with respect to (i) any alleged violation by any member of the Regulated Group of any law,
regulation or FDA order, or (ii) any alleged failure by any member of the Regulated Group to
have all required permits, registration, licenses, authorizations and approvals.

3.15 Insurance. Seller maintains, and through the Closing Date will maintain,
adequate insurance including self-insurance insuring the Purchased Assets and the operations of the
Business. All policies of insurance of any kind maintained, owned or held by Seller which cover
the Purchased Assets or the Business are set forth in Schedule 3.15 hereto and such
policies are in full force and effect, all premiums with respect thereto covering all periods up to
and including the Closing Date have been paid, and no notice of cancellation or termination has
been received with respect to any such policy which has not been replaced on substantially similar
terms prior to the date of such cancellation or termination. The insurance policies to which
Seller is a party which cover the Purchased Assets or Seller’s Business are sufficient for
compliance with all requirements of applicable laws and all agreements to which Seller is a party
or by which Seller or the Purchased Assets may be bound. In the three years preceding the date of
this Agreement, Seller has not been refused any insurance with respect to the Purchased Assets or
the operations of Seller or had its coverage limited by any insurance carrier to which it has
applied for any such insurance or with which it has carried such insurance.

3.16 Accounts Receivable; Inventory.

(a) Accounts Receivable; Accounts Payable. All accounts receivable of Seller
pertaining to the Business are reflected properly on their books and records, are valid
receivables subject to no setoffs or counterclaims, are current and collectible, and will be
collected in accordance with their terms at their recorded amounts, subject only to the
reserve for bad debts set forth on the face of the most recent balance sheet included in the
Financial Statements (the “Balance Sheet”) (rather than in any notes thereto) as
adjusted for the passage of time through the Closing Date in accordance with the past custom
and practice of Seller. Schedule 3.16(a) sets forth a complete and accurate list of
all outstanding accounts receivable pertaining to the Business as of the date of this
Agreement, which list sets forth the aging of such accounts receivables.

(b) Inventory. The inventories of Seller pertaining to the Business are
generally of a quality and quantity usable and salable at customary gross margins and with
customary markdowns consistent with past practice in the ordinary course of business. Such
inventory status is consistent with the past custom and practice of the

 

-11-

 

Seller, subject only to the reserve for inventory writedown set forth on the face of
the Balance Sheet (rather than in any notes thereto) as adjusted for the passage of time
through the Closing Date in accordance with the past custom and practice of Seller. Since
December 31, 2006, there have not been any write-downs of the value of, or establishment of
any reserves against, any inventory, except for write-downs and reserves in the ordinary
course of business and consistent with past practice which have not had, either individually
or in the aggregate, a material adverse effect.

(c) Accounts Payable. Schedule 3.16(c) contains a complete and
accurate list of all accounts payable which are included in the Assumed Liabilities as of
the date of this Agreement, which list sets forth the aging of each such account payable.
All accounts payable that are reflected on Schedule 3.16(c), or on the accounting
records of Seller as of the Closing Date represent valid obligations arising from products
or services actually received by or loans actually made to Seller in the ordinary course of
business.

3.17 Labor Matters. Except as set forth in Schedule 3.17: (a) to Seller’s and
Shareholder’s knowledge, Seller is in compliance in all material respects with all applicable laws
respecting employment and employment practices, terms and conditions of employment and wages and
hours, and is not engaged in any unfair labor practice; (b) there is no unfair labor practice
complaint against Seller pending or threatened with respect to Seller’s employees before the
National Labor Relations Board or any other applicable tribunal; and (c) Seller has received no
notice that any representation or petition respecting the employees of Seller has been filed with
the National Labor Relations Board or any other applicable tribunal.

3.18 Condition of Purchased Assets. The Purchased Assets are in good repair and
working condition, normal wear and tear excepted, are suited for the uses currently intended, are
in conformity with all applicable laws, ordinances, rules and regulations and are in good saleable
condition, normal wear and tear excepted.

3.19 Environmental Matters.

(a) Except as set forth in Schedule 3.19 hereto: (i) to Seller’s and
Shareholder’s knowledge, Seller is in compliance in all material respects with all
environmental laws, regulations, permits and orders applicable to it, and with all laws,
regulations, permits and orders governing or relating to asbestos removal and abatement;
(ii) Seller has not transported, stored, treated or disposed, or allowed or arranged for any
third parties to transport, store, treat or dispose, of any Hazardous Substances or other
waste to or at any location other than a site lawfully permitted to receive such Hazardous
Substances or other waste for such purposes, or had performed, arranged for or allowed by
any method or procedure such transportation, storage, treatment or disposal in contravention
of any laws or regulations, nor has Seller disposed of, or allowed or arranged for any third
parties to dispose of, Hazardous Substances or other waste upon property owned or leased by
it; (iii) to Seller’s and Shareholder’s knowledge, there has not occurred, nor is there
presently occurring, a Release of any Hazardous Substance on, into or beneath the surface of
any parcel of real property in which Seller has an ownership interest or any leasehold
interest; (iv) Seller has not transported or disposed of,

 

-12-

 

or allowed or arranged for any third parties to transport or dispose of, any Hazardous
Substance or other waste to or at a site which, pursuant to the U.S. Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended
(“CERCLA”) or any similar law, (A) has been placed on the National Priorities List
or its state equivalent, or (B) the Environmental Protection Agency or the relevant state
agency has proposed or is proposing to place on the National Priorities List or its state
equivalent; (v) Seller or Shareholders have not received notice, and have no knowledge of
any facts which could give rise to any notice, that Seller is a potentially responsible
party for a Federal or state environmental cleanup site or for corrective action under
CERCLA or any other applicable law or regulation or notice of any other Environmental Claim;
(vi) Seller has not received any written or oral request for information in connection with
any Federal or state environmental cleanup site and has not undertaken (or been requested to
undertake) any response or remedial actions or cleanup actions of any kind at the request of
any Federal, state or local governmental entity, or at the request of any other person or
entity; (vii) there are no laws, regulations, ordinances, licenses, permits or orders
relating to environmental or worker safety matters requiring any work, repairs, construction
or capital expenditures with respect to the assets or properties of Seller; and (viii)
Schedule 3.19 identifies (w) all environmental audits, assessments or occupational
health studies undertaken by Seller or its agents or by any governmental agencies with
respect to the operations or properties of Seller; (x) the results of any ground water,
soil, air or asbestos monitoring undertaken with respect to any real property owned or
leased by Seller; (y) all written communications of Seller with environmental agencies; and
(z) all citations issued to Seller under the Occupational Safety and Health Act (29 U.S.C.
Sections 651 et seq.).

(b) For the purposes of this Agreement, “Environmental Claim” shall mean any
demand, claim, governmental notice or threat of litigation or the actual institution of any
action, suit or proceeding at any time by a person other than the parties which asserts that
an Environmental Condition constitutes a violation of or otherwise may give rise to any
liability or obligation under, any statute, ordinance, regulation, or other governmental
requirement or the common law, including, without limitation, any such statute, ordinance,
regulation, or other governmental requirement relating to the emission, discharge, or
release of any Hazardous Substance into the environment or the generation, treatment,
storage, transportation, or disposal of any Hazardous Substance. “Environmental
Condition” shall mean the presence on the Closing Date, whether discovered or
undiscovered on the Closing Date, in surface water, ground water, drinking water supply,
land surface, subsurface strata or ambient air of any pollutant, contaminant, industrial
solid waste or Hazardous Substance arising out of or otherwise related to the operations or
other activities of Seller, or of any predecessor in interest or line of business to Seller,
conducted or undertaken prior to the Closing Date. “Hazardous Substance” shall mean
any substance defined in the manner set forth in Section 101(14) of the U.S. Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended, and shall
include any additional substances designated under Section 102(a) thereof.
“Release” shall mean releasing, spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, dumping or disposing into the
environment.

 

-13-

 

3.20 Absence of Certain Payments. Neither Seller nor Shareholders nor any officers,
directors, employees, agents, representatives, or independent contractors of the Seller has made,
or arranged for the making of, any unlawful payment to any official, officer or employee of any
foreign, Federal, state, county, municipal or other governmental or regulatory body or authority or
any self regulatory body or authority, or made any payment to any customer or supplier of the
Seller or any officer, director, partner, employee or agent of any customer or supplier, for the
unlawful sharing of fees or to any such customer or supplier or any such officer, director,
partner, employee or agent for the unlawful rebating of charges, or engaged in any other unlawful
reciprocal practice, or made any other unlawful payment or given any other unlawful consideration
to any such customer or supplier or any such officer, director, partner, employee or agent, in
respect of the Seller.

3.21 Full Disclosure. All information furnished to Buyer in accordance herewith is,
and as of the Closing Date shall be, correct and complete in all material respects. No
representation or warranty of Seller and no information, Schedule or certificate furnished or to be
furnished by or on behalf of Seller to Buyer, its affiliates or its agents pursuant to or in
connection with this Agreement contains or will contain any untrue statement of a material fact or
omits or will omit to state a material fact necessary in order to make the statements contained
herein or therein not misleading.

ARTICLE IV

REPRESENTATIONS, WARRANTIES AND COVENANTS OF BUYER

Buyer hereby represents and warrants to, and covenants with, Seller and Shareholders:

4.01 Organization. Buyer is a corporation duly organized, validly existing and in
good standing under the laws of the Republic of Ireland, and has the corporate power and authority
to own and operate its properties and assets and to conduct its business as it is now being
conducted. Buyer is duly qualified to do business in all other jurisdictions in which Buyer owns,
leases or operates property or otherwise conducts Buyer’s business if the failure to be qualified
would have a material adverse effect on Buyer’s ability to conduct business using the Purchased
Assets.

4.02 Due Authorization. Buyer has full corporate power and authority to enter into
this Agreement and the Related Agreements and to consummate the transactions contemplated hereby
and thereby and to perform its obligations hereunder and thereunder. The execution, delivery and
performance of this Agreement and the Related Agreements, and the consummation of the transactions
contemplated hereby and thereby, have been duly authorized by all necessary corporate action on the
part of Buyer. This Agreement has been duly executed and delivered by Buyer, and is a valid and
binding obligation of Buyer enforceable against Buyer in accordance with its terms. The execution,
delivery and performance of this Agreement and the Related Agreements will not conflict with or
result in a violation of any provision of the Certificate of Incorporation or By-Laws (or similar
corporate organizational documents) of Buyer, or of any material contract by which it is bound, or
of any judgment or decree to which it

 

-14-

 

is a party or by which it is bound. All necessary authorizations of the transactions
contemplated by this Agreement and the Related Agreements required to be obtained by Buyer from any
Federal, state, local or foreign government or agency shall have been obtained prior to the
Closing, and any filings, notifications or disclosures required by law or regulations of such
government or agency shall have been made in such form as is acceptable to file, provided that
Seller cooperates with Buyer with respect to the aforesaid filings, notifications or disclosures to
the extent necessary to obtain said authorizations. Buyer will deliver to Seller at the Closing
true and complete copies of all resolutions of its board of directors by which the execution,
delivery and performance of this Agreement and the Related Agreements and consummation of the
transactions contemplated hereby and thereby were authorized, certified by the Secretary of Buyer
as of the Closing Date.

ARTICLE V

COVENANTS PENDING CLOSING AND OTHER AGREEMENTS

5.01 Conduct of Business of Seller Prior to the Closing. Except as contemplated by
this Agreement, during the period from the date of this Agreement to the Closing Date, Seller will
conduct Seller’s Business and operations in, and only in, the ordinary course of business and
substantially in the manner heretofore conducted. Without limiting the generality of the
foregoing, and except as contemplated in this Agreement, prior to the Closing Date, without the
prior written consent of Buyer, Seller will not:

(a) incur or assume any indebtedness for money borrowed, including obligations in
respect of capital leases; or incur any material liabilities or obligations other than in
the ordinary course of business consistent with past practices; or assume, guarantee,
endorse or otherwise become liable or responsible (whether directly or contingently or
otherwise) for the obligations of any person; provided, that Seller may endorse
negotiable instruments for collection in the ordinary course of business;

(b) except in the ordinary course of business with product purchasers, enter into any
material contract or arrangement providing for, in the aggregate, payment or receipt of more
than US$25,000 or which is greater than six months in duration without Buyer’s consent which
shall not be unreasonably withheld or delayed;

(c) in any material way, violate, breach or allow to lapse any Material Contract or
enter into any other agreement, commitment or transaction (including without limitation any
borrowing, capital expenditure or capital financing), except in the ordinary course of
business consistent with past practice;

(d) sell, transfer, mortgage, encumber or otherwise dispose of any of the Purchased
Assets, except in the ordinary course of business consistent with past practice;

(e) agree or make any commitment to take any actions prohibited by this Section
5.01; or

 

-15-

 

(f) materially reduce the inventory set forth on Schedule 1.01(b) or the
accounts receivable set forth on Schedule 1.01(d).

5.02 Access to Information. Between the date of this Agreement and the Closing Date,
Seller will, during ordinary business hours (a) give Buyer and its authorized representatives and
advisors access to all books, records, offices and other facilities and properties of Seller, (b)
permit Buyer to make such inspections thereof as Buyer may reasonably request, and (c) cause its
officers and advisors to furnish Buyer with such financial and operating data and other information
with respect to Seller as Buyer may from time to time reasonably request; in addition, Seller will
cause its accountants to make their personnel, their work papers and such other requested
documentation relating to their work papers and to their audits, if any, of the books and records
of Seller available to Buyer and its advisors and representatives.

5.03 Consents. The parties hereto will use their best efforts to promptly obtain
consents (including any required consents to the assignment of contracts) of all persons and
governmental authorities necessary for the consummation of the sale of the Purchased Assets and the
other transactions contemplated by this Agreement and the Related Agreements.

5.04 Public Announcements. From the date hereof through the Closing, no party hereto
shall make any press release or public announcement or any disclosure to any third person (other
than to employees of Seller, employees of Buyer, attorneys, accountants and other advisors of the
parties hereto in connection with the transactions contemplated hereby) concerning the transactions
contemplated by this Agreement; provided, however, that the parties will make such
announcements, if any, as are required by applicable law or stock exchange rules and will mutually
agree to the content thereof. In conjunction with the Closing, Buyer and Seller shall consult with
each other concerning the form of any post-closing press release or any other public announcement
concerning the transactions contemplated by this Agreement, and the parties shall use their best
efforts to cause a mutually agreeable form of such release or announcement to be issued.

5.05 Confidentiality.

(a) All information furnished by Buyer (or its agents and representatives) to Seller or
Shareholders (or their agents and representatives) or furnished by Seller or Shareholders
(or their agents or representatives) to Buyer (or its agents and representatives) pursuant
hereto shall be treated as the sole property of the party furnishing the information until
the Closing Date, and if the Closing shall not occur, the party receiving the information
shall return to the party which furnished such information all copies of any documents or
other materials containing, reflecting or referring to such information, shall keep
confidential all of such information regarded as confidential by the party supplying such
information, and shall not directly or indirectly use such information for any competitive
or other commercial purpose. The obligation to keep such information confidential shall not
apply to (i) any information which (w) the party receiving the information can establish was
already in its possession prior to the disclosure thereof by the party furnishing the
information, (x) was then generally known

 

-16-

 

to the public, (y) became known to the public through no fault of the party receiving
the information; or (z) was disclosed to the party receiving the information by a third
party not bound by an obligation of confidentiality to the party furnishing the information;
or (ii) disclosures in accordance with an order of a court of competent jurisdiction or as
required by any law, rule or regulation applicable to the party making the disclosure,
including any rule of, or agreement of any party or its affiliates with, any stock exchange.

(b) Seller, Buyer and Shareholders agree, whether or not the Closing shall occur, to
maintain, and to cause their agents and representatives to maintain, the confidentiality of
the terms and conditions of this Agreement and the Related Agreements and all documents
executed and delivered in connection with the transactions contemplated by this Agreement
and the Related Agreements. The provisions of this Section 5.05(b) shall not apply
to particular conditions or terms of the above referenced documents (i) if the party seeking
to make such disclosure shall have obtained the prior written consent of the other party to
the disclosure of such conditions or terms, (ii) that are required to be disclosed during
the course of any litigation or arbitration which may be brought by any party related to the
provisions of any of the above referenced documents, (iii) that are or become generally
available to the public other than as a result of actions taken by the party seeking to make
such disclosure or its agents and representatives, or (iv) that are required to be disclosed
pursuant to and in accordance with any law, rule or regulation applicable to the party
seeking to make such disclosure, including any rule of, or agreement of any party or its
affiliates with, any stock exchange.

Notwithstanding the foregoing, if a party is requested or required (by oral questions,
interrogatories, requests for information or document subpoena, civil investigative demand or
similar process) to disclose any of the above-referenced documents, such party will promptly notify
the other party of such request so that such other party may seek an appropriate protective order
or waive compliance with the provisions hereof. If, in the absence of a protective order or the
receipt of a waiver hereunder, a party is nonetheless, in the opinion of its counsel, compelled to
disclose any terms or conditions of the above-referenced documents to any tribunal or else stand
liable for contempt or suffer other censure or penalty, such party may disclose such information to
such tribunal without liability hereunder.

5.06 Related Agreements. The parties hereto agree that at Closing they will execute
and deliver (or cause their affiliates to execute and deliver) the Related Agreements to which they
or their affiliates are to be a party.

5.07 No-Shop. Seller and Shareholders hereby agree that until September 30, 2007 they
shall not pursue or become involved in any negotiations or discussions or enter into any agreement
regarding the sale of the Business of Seller to any third person or entity.

5.08 Website. Immediately prior to Closing, Seller will have transferred from its
website www.cortex-biochem.com (to be transferred at Closing under Section
1.01(e)(i)) all contents related to the Magnetic Particle Business to a new website to be
established by Seller. Immediately after Closing, Buyer will include on the acquired website in a
reasonably prominent position a hyperlink to Seller’s newly established website for the Magnetic
Particle Business (the

 

-17-

 

“Hyperlink”). If Buyer does not include the Hyperlink on the website, Seller shall
give written notice to Buyer of its breach of this covenant. If Buyer does not include the
Hyperlink on the website within 30 days after receipt of such notice, Buyer shall sell the website
domain name to Seller for $1.00.

5.09 Licenses. Effective as of the Closing, Seller hereby grants to Buyer

(a) a royalty-free, non-revocable exclusive license used for the Business to use the
trade name “Cortex Immunoreagents” and a co-exclusive license used both for the Business and
the Magnetic Particle Business to use the trade name “Cortex Biochem” in relation to the
Business for a period of four years commencing on the Closing Date and Seller and Seller’s
successor-in-interest, if any to use the “Cortex Biochem” trade name in relation to the
Magnetic Particle Business; and

(b) a royalty-free, non-revocable and non-exclusive single use license to use the
software used both for the Business and the Magnetic Particle Business (the “Joint Use
Software”). In furtherance of providing this license, (a) promptly after Closing,
Seller shall cooperate reasonably with Buyer in providing Buyer with instruction and
training for how to use the Joint Use Software and (b) during the term of the license,
Seller shall provide reasonable support to Buyer for the Joint Use Software in a manner no
less responsive than if Seller were supporting its own use of the Joint Use Software.

5.10  Consulting Services. Dr. Matt Pourfarzaneh and Leonard I. Karp (the
“Shareholder Consultants”) will provide consulting services to the Buyer in relation to the
Business for a period of twelve months commencing on the Closing Date.

(a) Until the end of the sixth month after the Closing Date, the Shareholder
Consultants will not charge any consulting fees for the consulting services up to three
hours (for each Shareholder Consultant) in any given week. To the extent that a Shareholder
Consultant provides consulting services to the Buyer in excess of three hours in any given
week, Buyer will pay the Shareholder Consultant an hourly fee of $150 promptly upon (and in
no event later than 15 days after) presentation of a written invoice detailing the amount of
time spent (in time intervals of at least 1/4 hour) by the Shareholder Consultant in
performing the consulting services.

(b) After the end of the sixth month after the Closing Date, to the extent that a
Shareholder Consultant provides consulting services to the Buyer, Buyer will pay the
Shareholder Consultant an hourly fee of $150 promptly upon (and in no event later than 15
days after) presentation of a written invoice detailing the amount of time spent (in time
intervals of at least 1/4 hour) by the Shareholder Consultant in performing the consulting
services.

(c) Buyer will also reimburse the Shareholder Consultants for all expenses incurred by
them in the course of the consulting services and approved, in advance, by Buyer, including,
but not limited to, travel, lodging, meals, rental car etc.

 

-18-

 

ARTICLE VI

CLOSING CONDITIONS

6.01 Conditions to Each Party’s Obligations to Effect the Transactions Contemplated
Hereby. The respective obligations of each party to effect the transactions contemplated
hereby shall be subject to the fulfillment at or prior to the Closing Date of the following
conditions:

(a) No Order, Decree or Injunction. Neither Seller nor Buyer shall be subject
to any order, decree or injunction of a court of competent jurisdiction or governmental
agency and no statute, rule or regulation shall be in effect or be enacted or issued which
(i) prevents or delays any of the transactions contemplated by this Agreement, or (ii) would
impose any limitation on the ability of Buyer effectively to exercise full rights of
ownership of the Purchased Assets.

6.02 Conditions to the Obligations of Seller to Effect the Transactions Contemplated
Hereby. The obligations of Seller to effect the transactions contemplated hereby shall be
further subject to the fulfillment at or prior to the Closing Date of the following conditions, any
one or more of which may be waived by Seller:

(a) Covenants Performed; Representations and Warranties True. Buyer shall
have performed and complied with the covenants and agreements contained in this Agreement
required to be performed and complied with by it at or prior to the Closing Date and the
representations and warranties of Buyer set forth in this Agreement shall be true and
correct as of the Closing Date as though made at and as of the Closing Date, and Seller
shall have received a certificate to that effect signed on behalf of Buyer by an authorized
officer of Buyer;

(b) Due Authorization. Buyer shall have delivered to Seller resolutions of its
Board of Directors duly authorizing the transactions contemplated by this Agreement and the
Related Agreements, certified by the corporate Secretary of Buyer;

(c) Related Agreements. Buyer shall have executed and delivered, or shall have
caused to be executed and delivered, the Related Agreements.

(d) Purchase Price. Buyer shall have paid the Purchase Price.

6.03 Conditions to the Obligations of Buyer to Effect the Transactions Contemplated
Hereby. The obligations of Buyer to effect the transactions contemplated hereby shall be
further subject to the fulfillment at or prior to the Closing Date of the following conditions, any
one or more of which may be waived by Buyer:

(a) Covenants Performed; Representations and Warranties True. Seller and
Shareholders shall have performed and complied with the covenants and agreements contained
in this Agreement required to be performed and complied with by them at or

 

-19-

 

prior to the Closing Date, and the representations and warranties of Seller and
Shareholders set forth in this Agreement shall be true and correct as of the Closing Date as
though made at and as of the Closing Date, and Buyer shall have received, with respect to
Seller’s covenants, representations and warranties, a certificate to that effect signed by
authorized officers of Seller;

(b) Due Authorization. Seller shall have delivered to Buyer resolutions of its
Board of Directors and shareholders duly authorizing the transactions contemplated by this
Agreement and the Related Agreements, certified by the corporate Secretary of Seller;

(c) No Material Adverse Change. There shall not have been, since the date of
the Financial Statements, any material adverse change in the Business, results of
operations, financial condition or prospects of Seller with regard to the Business or the
Purchased Assets;

(d) Opinion Letter. Buyer shall have received an opinion or opinions from
counsel for Seller, dated the Closing Date and satisfactory in form and substance to Buyer
and its counsel.

(e) Related Agreements. All parties other than Buyer shall have executed and
delivered the Related Agreements, if any;

(f) Consents Obtained. Prior to Closing, all licenses, permits and other
governmental approvals and authorizations and all consents of third parties required to
effect the transactions contemplated by this Agreement, and for the Business of Seller to be
operated by Buyer after the Closing in the manner and to the extent of Seller’s current
operations (including, without limitation, all consents required for the assignment of the
Material Contracts referred to in Section 1.01(c)) shall have been obtained and
delivered to Buyer.

(g) Principal Supplier and Customer Due Diligence. Buyer shall have completed
due diligence discussions with Scantibodies, Seller’s principal customer, and Bioprocessing,
Inc., Seller’s principal supplier, and shall not have received any material adverse
information regarding the commercial relationship of either such party with the Business.

ARTICLE VII

THE CLOSING

7.01 Time and Place of Closing. Upon the terms and subject to the satisfaction or
waiver of the conditions in this Agreement, the Closing of the transactions contemplated hereby
(the “Closing”) shall take place no later than September 30, 2007 at the offices of Buyer’s
counsel, Carter Ledyard & Milburn LLP, Two Wall Street, New York, New York 10005, or at such other
time and place as the parties hereto may agree in writing. The effective time of the Closing is
herein referred to as the “Closing Date.”

 

-20-

 

7.02 Closing. At the Closing, Seller will deliver to Buyer such warranty deeds, bills
of sale, instruments of assignment, including instruments in the form of Exhibit A and
Exhibit B and other good and sufficient instruments of transfer and the other instruments
and documents contemplated hereby, executed by Seller and in form and substance reasonably
satisfactory to Buyer, as Buyer may reasonably require to vest in Buyer all right, title and
interest of Seller and their affiliates in and to the Purchased Assets, and Buyer shall pay to
Seller the Purchase Price, and deliver to Seller the other instruments and documents required of it
at the Closing.

Subject to the provisions of the Transition Services Agreement, Seller shall deliver to Buyer
at the Closing possession of the Purchased Assets being sold pursuant to this Agreement and the
entire right, title and interest of Seller in and to such Purchased Assets shall pass to Buyer at
the Closing.

ARTICLE VIII

EMPLOYMENT, WORKERS’ COMPENSATION AND

PRODUCT LIABILITY RESPONSIBILITY

8.01 Employment; Workers’ Compensation. Seller will retain the sole responsibility
for (i) the employment of its employees in the Business and the Magnetic Particle Business and any
obligations related thereto (including without limitation any pension or other employee benefit
obligations or liabilities), and (ii) all workers’ compensation claims of employees of Seller.

8.02 Product Liability and Warranty Claims. At the Closing, Buyer shall assume and
agree to perform and discharge all product liability and warranty claims (including claims for
injury to person or property) and litigation relating to the Business conducted by Buyer and
arising from products sold after the Closing Date.

8.03 Responsibility for Prior Claims. It is understood and agreed that Buyer does not
assume any liability for, and shall not otherwise be responsible for, any product liability or
warranty claims (including warranty claims for injury to person or property) arising from products
sold or occurrences on or prior to the Closing Date, and Seller and Shareholders agree to indemnify
and hold harmless Buyer with respect to any such claims as provided in Section 9.05.

ARTICLE IX

POST-CLOSING COVENANTS

9.01 Further Assurances. Subject to the terms and conditions of this Agreement, each
of the parties hereto will use its best efforts to take, or cause to be taken, all action, and to
do, or cause to be done, all things necessary, proper or advisable under applicable laws and
regulations to consummate and make effective the sale of the Purchased Assets and the other
transactions contemplated by this Agreement and the Related Agreements. From time to

 

-21-

 

time after the date hereof (including after the Closing Date if requested), Seller and its
affiliates will, at their own expense and without further consideration, execute and deliver such
instruments and documents to Buyer as Buyer may reasonably request in order more effectively to
vest in Buyer good title to the Purchased Assets and to more effectively consummate the
transactions contemplated by this Agreement and the Related Agreements. From time to time after
the date hereof, including after the Closing Date if requested, Buyer will, at its expense and
without further consideration, execute and deliver such instruments and documents to Seller as
Seller may reasonably request in order to more effectively consummate the transactions contemplated
hereby and the Related Agreements.

9.02 Commissions and Fees. Except as disclosed in Schedule 9.02 hereto,
Seller and Buyer each represent and warrant to the other that no broker, finder, financial adviser
or other person is entitled to any brokerage fees, commissions or finder’s fees in connection with
the transactions contemplated hereby by reason of any action taken by the party making such
representation. Seller on the one hand, and Buyer, on the other hand, will pay to the other or
otherwise discharge, and will jointly and severally indemnify and hold the other harmless from and
against, any and all claims or liabilities for all brokerage fees, commissions and finder’s fees
(other than as described above) incurred by reason of any action taken by such party.

9.03 Sales, Transfer and Use Taxes. All sales, transfer and use taxes incurred in
connection with this Agreement and the Related Agreements and the transactions contemplated hereby
and thereby will be borne by Seller, and Seller will, at its own expense, file all necessary tax
returns and other documentation with respect to all such sales, transfer and use taxes, and, if
required by applicable law, Buyer will join in the execution of any such tax returns or other
documentation.

9.04 Nondisclosure; Noncompetition.

(a) Seller and Shareholders agree not to use or disclose at any time after consummation
of the transactions contemplated hereby, except with the prior written consent of an officer
authorized to act in the matter by the Board of Directors of Buyer, any trade secrets,
proprietary information or other information relating to the Business that Buyer considers
confidential relating to designs, suppliers, inventions, operations, marketing, cost and
pricing data, master files or customer lists utilized by Seller prior to the Closing or by
Buyer or any of its affiliates (the “Buyer Group”), or the skills, abilities and
compensation of the Buyer Group’s employees, and all other similar information material to
the conduct of the Buyer Group’s business, which is not presently generally known to the
public; provided, however, that this provision shall not preclude Seller and
Shareholders from (i) the use or disclosure of such information (other than customer and
supplier lists) which presently is known generally to the public or which subsequently comes
into the public domain, other than by way of disclosure in violation of this Agreement or in
any other unauthorized fashion, or (ii) disclosure of such information required by law or
court order, provided that prior to such disclosure required by law or court order Seller
will give Buyer three business days’ written notice (or, if disclosure is required to be
made in less than three business days, then such notice shall be given as promptly as
practicable after determination that disclosure may be required) of the nature

 

-22-

 

of the law or order requiring disclosure and the disclosure to be made in accordance
therewith.

(b) For a period of three years from the Closing Date, Shareholders and Seller (the
“Seller Group”) shall not, without the written consent of an officer authorized to
act in the matter by the Board of Directors of Buyer, directly or indirectly: (i) own,
manage, operate, join, control, participate in, invest in, or otherwise be connected with,
in any manner, whether as an officer, director, employee, partner, investor, consultant,
lender or otherwise, any business entity which is engaged in, or is in any way competitive
with, the Business; or (ii)  on behalf of anyone else engaged in any such line of business
(x) persuade or attempt to persuade any employee of any member of the Buyer Group or any
individual who was an employee of any member of the Buyer Group during the one year prior to
the date of this Agreement, to leave the employ of any member of the Buyer Group or to
become employed by any person other than the members of the Buyer Group or hire any such
employee; (y) persuade or attempt to persuade any current client or former customer of any
member of the Buyer Group to cease doing business with, or to reduce the amount of business
it does or intends or anticipates doing with, Buyer (or any successor to Buyer’s business);
or (z) solicit the business of any of such customer or former customer with respect to the
Business conducted by Seller. Notwithstanding anything herein to the contrary, this Section
9(b) shall not prevent any member of the Seller Group from acquiring as an investment
securities representing not more than five percent (5%) of the outstanding voting securities
of any publicly-held corporation or from being a passive investor in any mutual fund, hedge
fund, private equity fund or similar pooled account so long as such person’s interest
therein is less than five percent (5%) and he has no role in selecting or managing
investments thereof.

9.05 Indemnification.

(a) By Founding Shareholders. Each Founding Shareholder agrees, in proportion
of his percentage ownership of Seller to the total percentage ownership of Seller held by
all of the Founding Shareholders, to save, defend and indemnify Buyer against and hold it
harmless from any and all claims, liabilities, losses, damages, deficiencies, costs and
expenses, of every kind, nature and description, fixed or contingent (including, without
limitation, interest, penalties and counsel’s fees and expenses in connection with any
action, claim or proceeding relating thereto or seeking enforcement of a party’s obligations
hereunder) (“Losses”), asserted against, resulting to, imposed upon or incurred by
Buyer, directly or indirectly, arising out of (i) any breach of any representation,
warranty, covenant or agreement made by Seller or Shareholders under this Agreement, or (ii)
any Retained Liability; provided, however, that (A) Shareholders shall not
have any obligation to indemnify Buyer from and against any Losses with respect to breaches
described in (i) above until Buyer has suffered aggregate Losses by reason of all such
breaches (excluding de Minimis Claims as hereinafter defined) in excess of $25,000, in which
event Buyer shall be entitled to indemnification for the full amount of its aggregate
Losses, (B) in no event shall the aggregate of Shareholders’ indemnification payments with
respect to breaches described in (i) above exceed the Purchase Price paid by Buyer
hereunder, and (C) indemnification claims with

 

-23-

 

respect to the representations and warranties contained in Article III hereof must be
made by Buyer within the survival period therefor specified in Section 10.06 hereof.
The foregoing limitations shall not apply with respect to any Losses arising out of any
Retained Liability or any Losses arising out of a breach of Section 3.05 (Taxes),
Section 3.10 (ERISA) or Section 3.19 (Environmental). For purposes hereof,
“de Minimis Claims” shall mean any indemnification claim for which the amount of
Losses claimed is less than $5,000 (providing that any series of claims arising from the
same or substantially similar facts or circumstances shall be treated as one claim for such
determination).

(b) By Buyer. Buyer agrees to save, defend and indemnify Seller against and
hold it harmless from any and all Losses arising out of any breach of any representation,
warranty, covenant or agreement made by Buyer under this Agreement; provided,
however, that (A) Buyer shall not have any obligation to indemnify Seller from and
against any Losses with respect to breaches described above until Seller has suffered
aggregate Losses by reason of all such breaches (excluding de Minimis Claims) in excess of
$25,000, in which event Seller shall be entitled to indemnification for the full amount of
their aggregate Losses, and (B) in no event shall the aggregate of Buyer’s indemnification
payments with respect to breaches described above exceed the Purchase Price paid by Buyer
hereunder, and (C) indemnification claims with respect to the representations and warranties
contained in Article IV hereof must be made by Seller within the survival period therefor
specified in Section 10.06 hereof.

9.06 Defense of Claims.

(a) Should any claim, action or proceeding by or involving a third party arise after
the Closing Date for which any party (the “Indemnifying Party”) is liable for
indemnification under the terms of this Agreement, the other party (the “Indemnified Party”)
shall notify the Indemnifying Party within a reasonable time after such claim, action or
proceeding arises and is known to the Indemnified Party (provided that the failure to give
timely notice shall not affect the right to indemnification hereunder except to the extent
that the Indemnifying Party is actually damaged or prejudiced by such delay), and if the
Indemnifying Party shall admit in writing its potential indemnification obligation in
respect thereof, the Indemnified Party shall give the Indemnifying Party a reasonable
opportunity:

(i) to take part in any examination of the books and records;

(ii) to conduct any proceedings or negotiations in connection therewith as necessary or
appropriate to defend the Indemnified Party or prosecute any claim, action, counterclaim or
other proceeding with respect thereto;

(iii) to take all other required steps or proceedings to settle or defend any such
claim, action or proceeding; and

(iv) to employ counsel to contest any such claim, action or proceeding in the name of
the Indemnified Party or otherwise.

 

-24-

 

The expenses of all proceedings, contests or lawsuits with respect to such claims or
actions shall be borne by the Indemnifying Party. If the Indemnifying Party wishes to
assume the defense and/or settlement of any such claim or action, it shall give written
notice to the Indemnified Party admitting the possibility of its indemnification obligation
in respect thereof and stating that it intends to assume such defense within 15 days after
notice from the Indemnified Party of such claim or action (unless the claim or action
reasonably requires a response in less than 15 days after notice thereof is given to the
Indemnifying Party, in which event it shall notify the Indemnified Party at least five days
prior to such reasonably required response date), and the Indemnifying Party shall
thereafter assume the defense of such claim or action, through counsel reasonably
satisfactory to the Indemnified Party; provided that the Indemnified Party may participate
in any such defense at its own expense. The Indemnified Party shall afford the Indemnifying
Party’s counsel and other authorized representatives reasonable access during normal
business hours to all books, records, offices and other facilities and properties of the
Indemnified Party, and to the personnel of the Indemnified Party, and shall otherwise use
all reasonable efforts to cooperate with the Indemnifying Party, such counsel and such other
authorized representatives in connection with the exercise of the rights of the Indemnifying
Party pursuant to this Section 9.06; provided, however, that prior
to the Indemnifying Party entering into any settlement arrangement it must first acknowledge
its obligation to indemnify the Indemnified Party.

(b) If the Indemnifying Party shall not assume the defense of, or if after so assuming
it shall fail to actively defend, any such claim or action, the Indemnified Party may defend
against any such claim or action in such manner as it may deem appropriate, and the
Indemnified Party may settle such claim or action on such terms as it may deem appropriate,
and the Indemnifying Party promptly shall reimburse the Indemnified Party for the amount of
such settlement and for all expenses, legal and otherwise, reasonably and necessarily
incurred by the Indemnified Party in connection with the defense against and settlement of
such claim or action. If no settlement of such claim or action is made, the Indemnifying
Party shall satisfy any judgment rendered with respect to such claim or in such action,
before the Indemnified Party is required to do so, and pay all expenses, legal or otherwise,
reasonably and necessarily incurred by the Indemnified Party in the defense against such
claim or action.

(c) If a judgment is rendered against the Indemnified Party in any action covered by
the indemnification hereunder, or any lien attaches to any of the assets of the Indemnified
Party, the Indemnifying Party immediately upon such entry or attachment shall pay such
judgment in full or discharge such lien unless, at the Indemnifying Party’s expense and
direction, an appeal is taken under which the execution of the judgment or satisfaction of
the lien is stayed. If and when a final judgment is rendered in any such action, the
Indemnifying Party shall forthwith pay such judgment before the Indemnified Party is
compelled to do so.

9.07 Expenses. Except as otherwise provided herein, Seller, Shareholders and Buyer
shall each bear their own costs and expenses incurred in connection with this Agreement, the
Related Agreements and the transactions contemplated hereby and thereby. Buyer shall be

 

-25-

 

responsible for the fees, commissions, expenses and reimbursements incurred by or required to
be paid to its and Buyer’s professional advisors, and Seller and Shareholders shall be responsible
for the fees, commissions, expenses and reimbursements incurred by or required to be paid to
Seller’s or Shareholders’ professional advisors, respectively.

9.08 Settlement of Seller’s Obligations. Seller will, after the Closing, duly settle
all its obligations, including accounts payable and employment related obligations. Buyer will,
after the Closing, duly settle all of the Assumed Liabilities.

ARTICLE X

MISCELLANEOUS

10.01 Binding Effect. This Agreement shall be binding upon and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

10.02 No Assignment. This Agreement may not be assigned by any party hereto without
the prior written consent of the other parties, provided, however, that each party
may assign its rights, but not its obligations, hereunder, in whole or in part, to any corporation
or other entity controlled by, controlling or under common control with such party, and such party
or its assignee may assign their rights hereunder, in whole or in part, to any purchaser of
substantially all of the assets or business of such party or such assignee. Any attempted or
purported assignment by either party other than in accordance with this Section 10.02 shall
be null and void. Nothing herein is intended to prohibit Seller from assigning the proceeds of the
sale hereunder to a third party.

10.03 Counterparts. This Agreement may be executed in any number of counterparts, and
by any party on separate counterparts, each of which as so executed and delivered shall be deemed
an original but all of which together shall constitute one and the same instrument, and it shall
not be necessary in making proof of this Agreement as to any party hereto to produce or account for
more than one such counterpart executed and delivered by such party. Execution by facsimile or pdf
signature shall be deemed to be, and shall have the same effect as, execution by original
signature.

10.04 Governing Law. This Agreement shall be governed by and construed in accordance
with the internal substantive laws of the State of New York (without regard to conflict of law
principles) as to all matters, including but not limited to matters of validity, construction,
effect, performance and remedies.

10.05 Suits in California. The parties agree that any action or proceeding relating
in any way to this Agreement or the Related Agreements or the transactions contemplated hereby and
thereby shall be brought and enforced in either the state or federal district courts for the State
of California, and the parties hereby waive any objection to jurisdiction or venue in any such
proceeding commenced in or removed to such courts.

 

-26-

 

10.06 Survival. The representations, warranties, indemnities and agreements of the
parties to this Agreement contained herein or in any document delivered pursuant to or in
connection herewith shall survive the Closing for two years and shall survive any investigation by
any party hereto; provided, however, that the representations and warranties of
Seller contained in Section 3.05 (Taxes), Section 3.10 (ERISA) and Section
3.19 (Environmental) shall survive until the expiration of the relevant statute of limitations.
The covenants contained in Section 5.05 and Article IX shall survive the Closing
indefinitely, except as otherwise provided therein.

10.07 Notices. All notices required to be given under the terms of this Agreement or
which any of the parties desires to give hereunder shall be in writing and personally delivered or
sent by registered or certified mail, return receipt requested, or sent by overnight courier, or
sent by fax addressed as follows:

	 	(a)	 	To Buyer. If to Buyer addressed to:

	 
	 	 	 	Benen Trading Ltd.

c/o Trinity Biotech plc

IDA Business Park

Southern Cross Road

Bray, County Wicklow

Ireland

Fax: 011-353-1267-9883

Attn: Mr. Rory Nealon

With a copy to:

Carter Ledyard & Milburn LLP

2 Wall Street

New York, New York 10005

Fax: 212-732-3232

Attn: Alan J. Bernstein, Esq.

	 	(b)	 	To Seller. If to Seller addressed to:

	 
	 	 	 	Cortex Biochem, Inc.

1933 Davis Street, Suite 311

San Leandro, CA 94577

Fax: 510-568-2467

Attn: Dr. Matt Pourfarzaneh, Ph.D.

With a copy to:

 

-27-

 

Randick O’Dea & Tooliatos, LLP

5000 Hopyard Road, Suite 400

Pleasanton, CA 94588

Fax: 925-460-0960

Attn: Robert Randick, Esq.

Any party may designate a change of address at any time by giving written notice thereof to
the other parties.

10.08 Amendment and Modification. This Agreement may be amended, modified or
supplemented only by a written instrument executed by all of the parties hereto.

10.09 Waiver of Compliance. Except as otherwise provided in this Agreement, any
failure of any of the parties to comply with any obligation, covenant, agreement or condition
herein may be waived by the party or parties entitled to the benefits thereof only by a written
instrument signed by the party or parties granting such waiver, but any such waiver or the failure
to insist upon strict compliance with any obligation, covenant, agreement or condition herein,
shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure or
breach.

10.10 Interpretation. The table of contents and the article and section headings
contained in this Agreement are solely for the purpose of reference, are not part of the agreement
of the parties and shall not in any way affect the meaning or interpretation of this Agreement. As
used in this Agreement, the term “person” shall mean and include an individual, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization or a governmental entity or
any department or agency thereof. As used in this Agreement, the term “subsidiary,” when used in
reference to any other person, shall mean any corporation of which outstanding securities having
ordinary voting power to elect a majority of the Board of Directors of such corporation are owned
directly or indirectly by such other person. As used in this Agreement, the term “GAAP” means
generally accepted accounting principles as in effect and as applied in the United States with
respect to Seller or Ireland with respect to Buyer or any of its affiliates. As used in this
Agreement, the term “affiliate” shall have the meaning set forth in Rule 12b-2 of the General Rules
and Regulations under the Securities Exchange Act of 1934. When used herein, the masculine,
feminine or neuter gender and the singular or plural number shall each be deemed to include the
others whenever the context so indicates or permits.

10.11 Entire Agreement. This Agreement and the Related Agreements, including the
schedules, exhibits, documents, certificates and instruments referred to herein and therein, embody
the entire agreement and understanding of the parties hereto in respect of any transactions
contemplated by this Agreement and the Related Agreements and supersede all prior agreements,
representations and understandings among the parties with respect thereto or with respect to the
transactions contemplated hereby.

 

-28-

 

10.12 Specific Performance.

(a) Seller and Shareholders acknowledge that, in view of the uniqueness of the Business
of Seller and the transactions contemplated hereby, Buyer may not have an adequate remedy at
law for money damages in the event that this Agreement with respect to the sale of the
Purchased Assets has not been performed in accordance with its terms by Seller or
Shareholders and therefore Seller and Shareholders agree that Buyer shall be entitled to
specific enforcement of the terms hereof with respect to the sale of the Purchased Assets
and the other transactions contemplated hereby in the event of breach by Seller or
Shareholders, respectively, in addition to any other remedy to which Buyer may be entitled,
at law or in equity, for such breach.

(b) In the event of a breach or threatened breach by the Seller Group of their
covenants under Section 9.04 hereof, Seller and Shareholders acknowledge that Buyer
may not have an adequate remedy at law for money damages. Accordingly, in the event of such
breach or threatened breach, Buyer will be entitled to such equitable and injunctive relief
as may be available to restrain the Seller Group from the violation of the provisions of
said Section 9.04 in addition to any other remedy to which Buyer may be entitled, at
law or in equity, for such breach or threatened breach.

10.13 Severability of Covenants. Seller and Shareholders acknowledge that the
covenants contained in Section 9.04 of this Agreement are reasonable and necessary for the
protection of Buyer and its investment in the Purchased Assets and that each covenant, and the
period or periods of time and the types and scope of restrictions on the activities specified
therein are, and are intended to be, divisible and shall be deemed a series of separate covenants,
one for each state or jurisdiction to which they are applicable. In the event that any provision
of this Agreement, including any sentence, clause or part hereof, shall be deemed contrary to law
or invalid or unenforceable in any respect by a court of competent jurisdiction, the remaining
provisions shall remain in full force and effect to the extent that such provisions can still
reasonably be given effect in accordance with the intentions of the parties, and any invalid and
unenforceable provisions shall be deemed, without further action on the part of the parties,
modified, amended and limited solely to the extent necessary to render the same valid and
enforceable.

ARTICLE XI

TERMINATION AND ABANDONMENT

11.01 Termination. This Agreement may be terminated at any time prior to the Closing:

(a) by the written agreement of all of the parties hereto;

(b) by Buyer if there has been a material violation or breach by Seller or Shareholders
of any covenant, agreement, representation or warranty contained in this Agreement entitling
Buyer not to close under Article VI;

 

-29-

 

(c) by Seller or Shareholders if there has been a material violation or breach by Buyer
of any covenant, agreement, representation or warranty contained in this Agreement entitling
Seller not to close under Article VI; or

(d) by either Buyer or Seller or Shareholders if the Closing of the transactions
contemplated by this Agreement shall not have been consummated on or before September 30,
2007, provided, however, that termination pursuant to this subsection (d)
shall not relieve any party of the liabilities contemplated by the proviso to the second
sentence of Section 11.02 hereof, if applicable.

11.02 Procedure and Effect of Termination. In the event of termination of this
Agreement and abandonment of the transactions contemplated hereby by any of the parties pursuant to
Section 11.01(b), (c) or (d) of this Agreement, written notice thereof shall forthwith be
given by the terminating party to the other parties and this Agreement shall terminate and the
transactions contemplated hereby shall be abandoned, without further action by any of the parties
hereto. If this Agreement is properly terminated, none of the parties hereto nor any of their
respective directors, officers or affiliates, as the case may be, shall have any liability or
further obligation to any of the other parties or any of their respective directors, officers or
affiliates, as the case may be, pursuant to this Agreement; provided, however, that
if any such termination shall result from the breach of a warranty or the failure of a party to
fulfill a condition to the performance of the obligations of the other parties or to perform a
covenant or agreement contained in this Agreement or from any other willful breach by any party to
this Agreement, such party shall be solely liable for any and all damages, costs and expenses
(including, but not limited to, counsel’s fees) sustained or incurred by the other parties as a
result of such failure or breach. The provisions of Sections 5.05, 10.04, 10.05, 10.07,
10.13 and 11.02 shall survive any termination hereof.

[Signature Page Follows]

 

-30-

 

IN WITNESS WHEREOF, the parties have each caused this Agreement to be executed by their duly
authorized officers as of the date first above written.

	 	 	 	 	 
	 	BENEN TRADING LTD.

 	 
	 	By:  	/s/ Rory Nealon
 	 
	 	 	Name:  	Rory Nealon 	 
	 	 	Title:  	CFO 	 
	 
	 	CORTEX BIOCHEM, INC.

 	 
	 	By:  	/s/ Matt Pourfarzaneh
 	 
	 	 	Name:  	Dr. Matt Pourfarzaneh 	 
	 	 	Title:  	President 	 
	 	 	 
	 	
/s/ Matt Pourfarzaneh
 	 
	 	DR. MATT POURFARZANEH 	 
	 	 	 
	 	
/s/ Leonard I. Karp
 	 
	 	LEONARD I. KARP 	 
	 	 	 
	 	                                                 /s/ Edward J. Ritelli, Jr.
 	 
	 	EDWARD J. RITELLI, JR. 	 
	 	 	 
	 	                                                 /s/ Ray Pourfarzaneh
 	 
	 	RAY POURFARZANEH 	 
	 	 	 
	 	
/s/ Dr. Dokhi Nargessi
 	 
	 	DR. DOKHI NARGESSI 	 

 

-31-Exhibit 10.2

Exhibit 10.2

THIS AGREEMENT is made the fourth day of October, Two Thousand and Seven

BETWEEN:

	(1)	 	Ken Frizelle, Trevor Frizelle, Kevin Frizelle, James Frizelle and Dianne Frizelle trading in
partnership as Sterilab Services (“the Vendor”) and

	(2)	 	Trinity Biotech (UK Sales) Limited (Company Number 4524238) whose registered office is at
Salisbury House, 54 Queens Road, Reading, RG1 4AZ (“the Purchaser”)

WHEREAS

	(A)	 	The Vendor carries on the Business under the Business Name

	(B)	 	The Vendor has agreed with the Purchaser for the sale to the Purchaser of the business and of
its assets on the terms set out in this Agreement

NOW IT IS HEREBY AGREED as follows:

	1.	 	DEFINITIONS

	 	1.1.	 	In this Agreement

	 	1.1.1.	 	“the Assets” means collectively the Goodwill, Fixtures and Fittings, Field
Instrumentation and the Stocks

	 	1.1.2.	 	“the Book Debts” means all book and other debts accrued or accruing due to the Vendor
in respect of the Business as at the Completion Date

	 	1.1.3.	 	“the Business” means the professional products business of the Vendor being the sales
and distribution of Trinity infectious disease diagnostic products carried on under the
Business Name at the date of this agreement

	 
	 	1.1.4.	 	“the Business Name” means “Sterilab” and/or “Sterilab Services”

	 	1.1.5.	 	“Completion” means the performance by the parties hereto of their respective
obligations under the terms of this Agreement

	 
	 	1.1.6.	 	“Completion Date” means the date set out in clause 7

 

 

 

	 	1.1.7.	 	“Creditors” means the aggregate amount owed by the Vendor in connection with the
Business to the Completion Date

	 	1.1.8.	 	“Disclosed” means fairly disclosed in such manner and with sufficient detail as would
enable a reasonable purchaser to make a reasonably informed and accurate assessment of
the nature and scope of the matter concerned

	 	1.1.9.	 	“Disclosure Letter” means the letter from the Vendors to the Purchaser of even date
herewith

	 	1.1.10.	 	“the Distribution Agreement” means the distribution agreement entered into on 14
January 2003 and made between Trinity Biotech Manufacturing Limited and the Vendor.

	 	1.1.11.	 	“The Employees” means the persons engaged in the Business as at the Completion Date
whose names and details are listed in Schedule 1

	 
	 	1.1.12.	 	“the Fixtures and Fittings” means the items listed in Schedule 2 hereto

	 	1.1.13.	 	“Field Instrumentation” means instruments owned by the Vendor which are located at
customers’ premises and are using reagents supplied by the Vendor. The details of these
instruments are shown in Schedule 3.

	 	1.1.14.	 	“the Goodwill” means the goodwill of the Vendor in connection with the Business and
the exclusive right for the Purchaser or its assignee to represent himself as carrying
on the Business in succession to the Vendor and the right to all lists of customers and
suppliers of the Business, standing orders and other documents and records relating
exclusively to the Business

	 	1.1.15.	 	“the Liabilities” means the liabilities of the Business outstanding at the Completion
Date

	 	1.1.16.	 	“Nominated Account” means account no 10104418, Sort Code 16-20-36, Account Name
Sterilab Services UK, Royal Bank of Scotland, Harrogate

	 	1.1.17.	 	“the Purchaser’s Solicitors” means Barrett & Co of 54 Queens Road, Reading, RG1 4AZ
(Ref SAB)

 

Page 2 of 30

 

	 	1.1.18.	 	“the Regulations” means the Transfer of Undertakings (Protection of Employment)
Regulations 2006

	 	1.1.19.	 	“the Stocks” means the stock-in-trade of the Business at the Completion Date and
printed promotional material related exclusively to the Business

	 	1.1.20.	 	“the Vendor’s Solicitors” mean Dickinson Dees of 121 The Mount, York, YO24 1DU (Ref
PA)

	 	1.1.21.	 	“the Warranties” means the warranties representations and undertakings set out in
clause 17 and Schedule 6

	 	1.1.22.	 	“Warranty Claim” means any claim by the Purchaser for breach of any of the Warranties

	 	1.2.	 	The headings in this Agreement are for convenience only and shall not affect the
interpretation hereof. References in this Agreement to clauses recitals or schedules are
to clauses of and recitals or schedules to this Agreement unless otherwise expressly
stated. Unless the context otherwise requires the singular shall include the plural and
vice versa the masculine shall include the feminine and references to persons shall include
bodies corporate unincorporated associations and partnerships. References in this
Agreement to any statute or statutory provision shall include any statute or statutory
provision which amends extends consolidates or replaces the same or which has been amended
extended consolidated or replaced by the same and shall include any order regulation
instrument or other subordinate legislation made under the relevant statute or statutory
instrument. Where the Purchaser includes one or more persons any covenant given by the
Purchaser is on a joint and several basis

 

Page 3 of 30

 

	2.	 	AGREEMENT FOR THE SALE AND PURCHASE

Subject to the provisions of this Agreement the Vendor shall sell with full title guarantee and the
Purchaser relying on the Warranties shall purchase free from all charges liens and encumbrances
with effect from the Completion Date the Business as a going concern comprising the following
assets for the consideration of £660,000 to which shall be added the additional consideration for
goodwill as set out in paragraphs 1.2 and 1.3 of Schedule 4 in respect of Sales and Incremental
Sales if any and in respect of Stock all of which shall be calculated and paid in accordance with
Schedule 4 and which shall be in respect of the following assets:

	 	2.1	 	The Goodwill

	 
	 	2.2	 	The Fixtures and fittings as listed in Schedule 2

	 
	 	2.3	 	The Field Equipment as listed in Schedule 3

	 	2.4	 	The Stocks calculated as in Schedule 4. In the event that acquired stocks with a shelf life
of less than 6 months on acquisition is not subsequently sold to third parties by the
Purchaser before expiry the Vendor will reimburse the Purchaser at cost for any such stock
items provided that the Purchaser shall use reasonable efforts to sell acquisition stock
before selling stock acquired after completion.

	 	2.5	 	all lists and data and particulars of suppliers, clients and customers, sales and stock
records, customer standing orders, price lists, catalogues, sales brochures, sales literature
and publicity material of the Business, technical know-how and all other documents relating
exclusively to the Business as the Purchaser may reasonably require to enable it effectively
to carry on the same in succession to the Vendor.

	 	2.6	 	without in any way limiting the generality of the foregoing all other assets (if any) of
whatever nature employed exclusively in the Business at the Completion Date but
excluding the Excluded Assets referred to in clause 4.

	3.	 	PASSING OF RISK AND TITLE

	 	3.1.	 	The risk and property in the Fixtures and Fittings shall not pass to the Purchaser
until the Completion Date

	 	3.2.	 	Notwithstanding anything hereinbefore contained to the extent that any of the Assets
hereby agreed to be sold are the subject of a lease and/or hire agreements and cannot
effectively be transferred to the Purchaser except with the consent of or by an agreement
of novation with one or more third parties the obligation of the Vendor to transfer the
same shall be conditional upon the consent of such third parties being received or (as the
case may be) such novation being effected and until such consent has been received or such
novation has been effected the Purchaser shall pending the transfer thereof perform all the
obligations of the Vendor under such lease or hire agreement and indemnify the Vendor
against all liabilities thereunder

 

Page 4 of 30

 

	4.	 	EXCLUDED ASSETS AND LIABILITIES

	 
	 	 	There shall be excluded from the sale and purchase and be retained by the Vendor:

	 	4.1.	 	all the statutory books and statutory records of the Vendor

	 	4.2.	 	all Book Debts and other debts (including VAT thereon) accrued or accruing due to the
Vendor in respect of the Business up to Completion

	 	4.3.	 	cash in hand or at the Bank at Completion

	 	4.4.	 	any amounts recoverable or payable in respect of taxation including Value Added Tax
attributable to periods ending on or before Completion

	 	4.5.	 	the Liabilities and the Creditors

	5.	 	APPORTIONMENTS OF PERIODICAL CHARGES AND ADJUSTMENTS TO THE AMOUNT OF THE
CONSIDERATION

All periodical charges and outgoings of the Business shall be apportioned on a time basis so that
such part of the relevant charges attributable to the period ending on Completion shall be borne by
the Vendor (as the case may require) and such part of the relevant charges attributable to the
period commencing on the day following Completion shall be borne by the Purchaser to the extent
such obligations are being assumed by the Purchaser

	6.	 	EMPLOYEES

The parties hereto acknowledge that no Employees are to transfer to the Purchaser but:

	 	6.1.	 	The Vendor shall indemnify the Purchaser against each and every cost claim liability
expense or demand arising from any claim or allegation by an Employee that in consequence
of the sale of the Business to the Purchaser there has been or will be a substantial change
in such Employee’s working conditions to his detriment

 

Page 5 of 30

 

	 	6.2.	 	If any contract of employment or engagement has effect as if originally made between
the Purchaser and any person or body or their representatives as a result of the provisions
of the Regulations or otherwise:

	 	6.2.1.	 	the Purchaser may terminate such contract or agreement and

	 
	 	6.2.2.	 	the Vendor shall indemnify and hold the Purchaser harmless against each and every
cost, claim, liability, expense or demand (including any liability to taxation
and legal and other professional fees and expenses) that the Purchaser may
suffer, incur, sustain or pay:

	 	(a)	 	by reason of, on account of or arising out of
such termination or

	 
	 	(b)	 	arising from such contract either before or after
the Completion Date if the Purchaser does not terminate such contract

	7.	 	COMPLETION

The
purchase shall be completed on the
        day of          Two Thousand and
Seven

	8.	 	COMPLETION DETAILS

	 	8.1.	 	Completion of the sale and purchase hereby agreed shall take place on the Completion
Date at the offices of the Vendor’s Solicitors or at such other time and/or place as the
Vendor’s Solicitors and the Purchaser’s Solicitors may mutually agree or at such other
place as the Vendor’s Solicitors may reasonably require

	 	8.2.	 	At Completion

	 	8.2.1.	 	The Vendor shall place the Purchaser in effective possession and control of the
Business and cause to be delivered to the Purchaser all the Assets which are capable
of passing by delivery

 

Page 6 of 30

 

	 	8.2.2.	 	The Vendor and the Purchaser shall enter into a Deed Of Novation of the
Distribution Agreement and the Purchaser shall procure that Trinity Biotech
Manufacturing Limited shall enter into the Deed of Novation

	 
	 	8.2.3.	 	The Vendor shall deliver to the Purchaser

	 	8.2.3.1.	 	a duly executed Assignment of the Goodwill

	 
	 	8.2.3.2.	 	all relevant information relating to the customers and suppliers of the
Business, including, but not limited to, detailed sales histories by customer

	 
	 	8.2.3.3.	 	all sales publications, advertising and promotional material and terms
and conditions of sale which relate exclusively to the Business, including a
soft copy of the most recent sales brochure

	 
	 	8.2.3.4.	 	Certificates of Non-Crystallisation relating to all financial charges
Mortgages or Debentures over the Assets

	 	8.3.	 	In return at Completion the Purchaser shall deliver to the Vendor’s Solicitors (who are
irrevocably authorised to receive the same) by telegraphic transfer to the Nominated Amount
the sums due to the Vendor hereunder pursuant to Clause 2 hereof

	 	8.4.	 	The Purchaser and Vendor shall undertake a joint stock take on the basis set out in
paragraph 3 of Schedule 4 on Completion and both parties shall agree the quantities of
Stock acquired for the purposes of calculating sums due to the Vendor in respect of the
Stock

	 	8.5.	 	Within 30 days of Completion the Purchaser shall deliver to the Vendor’s Solicitors
(who are irrevocably authorised to receive the same) by telegraphic transfer to the
Nominated Account the sums due to the Vendor hereunder in respect of the Stocks pursuant to
Clause 8.4 hereof less any sums due to Trinity Biotech Manufacturing Limited at Completion
under the terms of the Distribution Agreement

	 	8.6.	 	Within 30 days of Completion the Purchaser shall pay to the Vendor by telegraphic
transfer to the Nominated Account any additional goodwill consideration due in respect of
Sales and Incremental Sales such additional consideration to be calculated in accordance
with paragraphs 1.2 and 1.3 of Schedule 4.

 

Page 7 of 30

 

	9.	 	NO REPRESENTATION

The Purchaser admits that he has inspected the Fixtures and Fittings and the Stock and that he has
entered into this Agreement solely on the basis of that inspection and the terms of this Agreement
and not in reliance upon any other representation whether written or oral or implied made by or on
behalf of the Vendor other than such of the written information given to the Purchaser or
Purchaser’s Solicitors in reply to enquiries before contract or in reply to observations thereon

	10.	 	NON MERGER

This Agreement shall as to any of its provisions remaining to be performed or capable of having
effect following completion of the sale and purchase hereby agreed remain in full force and effect
notwithstanding completion of the sale and purchase

	11.	 	INTEREST

Interest on the balance of the payments referred to in Clause 2 which are not paid on their due
date shall accrue interest at the rate of 4% above National Westminster Bank plc base rate from
time to time

	12.	 	V.A.T 

The Vendor and Purchaser acknowledge and agree that the sale represents the transfer of a business
(or part of a business) as a going concern. The parties intend that the Value Added Tax Act 1994
Section 49 (“Section 49”) and the Value Added Tax (Special Provision) Order 1995 Article 5 as
amended (“Article 5”) shall apply to the transfer of the Business and

	 	12.1.	 	the Parties shall use all reasonable endeavours to secure that pursuant to Section 49
and Article 5 the sale of the Business is treated as neither a supply of goods nor a supply
of services for the purposes of VAT

	 
	 	12.2.	 	on Completion the Vendor shall deliver to the Purchaser all records relating to the
Business referred to in Section 49

 

Page 8 of 30

 

	 	12.3.	 	the Vendor warrants to the Purchaser that they are and will at completion be duly
registered for the purposes of VAT

	 
	 	12.4.	 	The Purchaser warrants that either:-

	 	12.4.1.	 	he is and will at completion be duly registered for the purpose of VAT; or

	 
	 	12.4.2.	 	he will be (as a result of completion) a taxable person for VAT purposes (within the
meaning of Section 3 of the Value Added Tax Act 1994)

	 	12.5.	 	In the event that VAT is chargeable on the transfer of any of the Assets pursuant to
this agreement then subject to the receipt by the Purchaser of a valid VAT invoice or
invoices relating to such Assets the Purchaser shall pay to the Vendor (in addition to the
consideration referred to in clause 2)

	 	12.5.1.	 	an amount equal to the amount of VAT payable in respect of the same; together with

	 
	 	12.5.2.	 	any penalty or interest incurred for late payment of such tax but only to the extent
that such late payment is caused by a breach by the Purchaser of the warranty contained
in clause 12.4 or by any failure by the Purchaser to fulfil or properly and timeously
carry out any obligation imposed upon him by this clause 12

	13.	 	VENDOR’S OBLIGATIONS AT AND AFTER COMPLETION

	 	13.1.	 	The Vendor will immediately after the Completion Date cease to carry on the Business
but (subject always to its obligations under the Insolvency Act 1986) will promptly pay all
creditors in a manner consistent with the way it did so prior to Completion

	 
	 	13.2.	 	The Vendor will at the request of the Purchaser and on reasonable notice be available
for a period of three months following the Completion Date to assist in the transition of
the customer base and/or to provide at cost consultancy services to the Purchaser in order
to assist Purchaser in its dealings with the Vendors customers so as to seek to preserve
the entirety of the Goodwill for the benefit of the Purchaser

 

Page 9 of 30

 

	14.	 	THE BOOK DEBTS

	 	14.1.	 	The Book Debts as at Completion shall remain respectively the property and
responsibility of the Vendor

	 	14.2.	 	The Vendor shall be entitled to collect the sums due to it from debtors for its own
account but the Vendor undertakes to the Purchaser that it will not issue or threaten to
issue any court or insolvency proceedings against any debtor in relation to any Book Debt
without giving at least 28 days prior written notice of its intention to do so to the
Purchaser and the Purchaser shall have the right to purchase the Book Debt in question
against payment to the Vendor of the full nominal amount thereof and the Vendor shall not
issue or threaten to issue any court or insolvency proceedings until the expiration of the
said period of 28 days.

	 	14.3.	 	The Vendor shall inform Purchaser of any amounts received by Vendor from customers in
respect of post acquisition sales and shall remit such amounts promptly to the Purchaser on
a weekly basis

	15.	 	CREDITORS AND LIABILITIES

	 	15.1.	 	The Vendor shall promptly discharge the Creditors and Liabilities and notwithstanding
Completion shall be solely responsible for all debts payable by and claims outstanding
against the Vendor or the Business to and including the Completion Date including (without
limitation) all sums payable under taxation statues and other expenses. The Vendor agrees
to indemnify the Purchaser fully at all times from and against any and all claims actions
proceedings demands liabilities costs and expenses in connection with any of the Creditors
or the Liabilities

	 	15.2.	 	The Vendor shall:

	 	15.2.1.	 	remain liable for and indemnify the Purchaser against claims by third parties in
respect of any goods or services supplied by the Vendor and any third party
liabilities including without limitation all reasonable, costs, claims, expenses which
it may incur as a result of anything done or omitted to be done by the Vendor prior to
the Completion Date in relation to the Assets, the employees or the Business

 

Page 10 of 30

 

	 	15.2.2.	 	upon becoming aware of any such claim the Vendor will promptly give notice of it to
the Purchaser and shall not take any steps which might reasonably be expected to damage
the commercial interest of the Purchaser without prior consultation with the Purchaser

	 	15.3.	 	The liability of the Vendor under clause 15.2.1 shall extend to any settlement by the
Purchaser of a claim (including costs) made with the written approval of the Vendor

	16.	 	TITLE

The Vendor shall take all necessary steps and co-operate fully with the Purchaser to ensure that it
obtains the full benefit of the Business and Assets and shall execute such documents and take such
other steps (or procure other necessary parties so to do) as are reasonably necessary or appropriate for vesting in
the Purchaser all its rights and interests in the Assets

	17.	 	WARRANTIES

	 	17.1.	 	The Vendor hereby undertakes represents and warrants to the Purchaser that save as
Disclosed in the Disclosure Letter each of the Warranties and of the statements set out
herein is at the date hereof true and accurate in all material respects

	 	17.2.	 	The Purchaser is entering this Agreement in reliance upon each of the Warranties which
the Vendor acknowledges

	 	17.3.	 	The Warranties shall remain in full force and effect after Completion

	 	17.4.	 	Each of the Warranties shall be construed as a separate and independent Warranty and
shall not be limited by reference to any other Warranty

	 	17.5.	 	The rights and remedies of the Purchaser in respect of any breach of the Warranties
shall not be affected by completion of the purchase of the Assets by any investigation made
by or on behalf of the Purchaser into the affairs of the Vendor by the Purchaser failing to
exercise or delaying the exercise of any of its rights or remedies or by any other event or
matter whatsoever except a specific and duly authorised written waiver or release

 

Page 11 of 30

 

	 	17.6.	 	Any Warranty qualified by expression such as “to the best of the Vendor’s knowledge
information and belief” or by references to the awareness of the Vendor shall be deemed to
include a statement that it is made after due and careful inquiry of Ken Frizelle, Trevor
Frizelle, Kevin Frizelle, James Frizelle or Dianne Frizelle .

	18.	 	WARRANTY LIMITATIONS

	 	18.1.	 	The Vendor shall not be liable under any provision in this Agreement:-

	 	18.1.1.	 	to the extent that the facts which might result in a claim or possible claim are
disclosed or referred to in the Disclosure Letter;

	 	18.1.2.	 	to the extent that a claim arises wholly or partly:-

	 	18.1.2.1.	 	from an act or omission occurring at the request of or with the consent of the
Purchaser;

	 
	 	18.1.2.2.	 	from an act or omission compelled by law;

	 	18.1.2.3.	 	as a result of the failure on the part of the Purchaser to make any claim,
election, surrender or disclaimer or give notice or consent to do any other thing
under the provisions of any law or regulation relating to Taxation after
Completion;

	 	18.1.2.4.	 	from any change in the nature of the Business or in the manner of conducting
the Business after Completion;

	 	18.2.	 	to the extent that the subject of the claim has been or is made good or is otherwise
compensated for without cost to the Purchaser;

	 	18.3.	 	to the extent to which the claim in question would not have arisen but for any matter
or thing done or omitted to be done by the Purchaser or persons deriving title from the
Purchaser on or after Completion;

 

Page 12 of 30

 

	 	18.4.	 	The Vendor shall not be liable in respect of any claim under this Agreement or in
respect of any misrepresentation relating to the sale of the Assets unless:-

	 	18.4.1.	 	the Vendor receives written notice of the claim which:-

	 	18.4.1.1.	 	is served on the Vendor before the first anniversary of the date of
Completion;

	 	18.4.1.2.	 	refers to the Warranty or provision in this Agreement or any misrepresentation
relating to the sale of the Assets which the Purchaser alleges has been breached or
upon which the Purchaser relies; and

	 	18.4.1.3.	 	gives reasonable details of the facts or events then known to the Purchaser
which the Purchaser alleges constitute the breach or give rise to the claim;

	 	18.4.1.4.	 	(subject to the Vendor and the Purchaser otherwise agreeing in writing) court
proceedings have been issued and properly served by the Purchaser against the
Vendor in respect of such claim within the period of 3 months immediately following
notification under clause 18.8

	 	18.5.	 	The aggregate liability of the Vendor in respect of all claims under this Agreement or
any misrepresentation relating to the sale of the Assets shall in no event exceeds
50(fifty) per cent of the purchase price set out in clause 2 above and no amount shall be
payable by the Vendor in respect of any such claim unless the amount of such claim exceeds
£10,000 (a “Qualifying Claim”).

	 	18.6.	 	If the Vendor at any time pays to the Purchaser an amount pursuant to a claim under
the provisions of this Agreement or in connection with any misrepresentation relating to
the sale of the Assets and the Purchaser subsequently becomes entitled to recover from some
other person any sum in respect of any matter giving rise to such claim the Purchaser shall
take necessary steps to enforce such recovery and shall immediately repay to the Vendor so
much of the amount paid by the Vendor to the Purchaser as does not exceed the sum recovered
from such other person less all costs, charges and expenses incurred by the Purchaser in
recovering that sum from such other person.

 

Page 13 of 30

 

	 	18.7.	 	The Purchaser shall inform the Vendor in writing of any event which comes to the
notice of the Purchaser or the Business whereby it appears that the Vendor is or is likely
to become liable under the provisions of this Agreement or any misrepresentation relating
to the sale of the Assets within twenty eight Business Days from the day upon which such
event is recognised by the Purchaser as being likely to give rise to a claim under this
Agreement or in connection with any misrepresentation relating to the sale of the Assets.
Where no notice is given by the Purchaser to the Vendor, this will not prejudice any claim
by the Purchaser happening before the first anniversary of the date of Completion, unless
absence of such notice is deemed to prejudice the Vendor’s own position. The Purchaser shall
take such action and give such information and assistance in connection with the affairs of
the Business as the Vendor may reasonably request to assist the Vendor to avoid, dispute,
resist, mitigate, compromise, defend or appeal against any claim in respect thereof and any
adjudication with respect thereto. The Vendor agrees to indemnify the Purchaser against any
costs arising in connection with such action. The conduct of any proceedings arising in
connection with any such claim shall be carried out by the Vendor provided always that
where any party to such proceedings (other than the Vendor) is at the time such proceedings
are commenced or are being pursued a material customer or supplier of the Business the
Vendor will consult with the Purchaser in relation to the conduct of such proceedings.

	 	18.8.	 	Where any claim against the Vendor under this Agreement or any misrepresentation
relating to the sale of the Business or the Assets arises in connection with a claim of any
nature made by a third party against the Purchaser or where the liability of the Vendor in
connection with any claim made against it under this Agreement or any misrepresentation
relating to the sale of the Business or the Assets, may be reduced by exercise by the
Purchaser of any rights which it might have against a third party, the negotiations
relating to and the conduct of any proceedings arising in connection with any such claim or
the exercise of such rights shall, if the Vendor requires and if the Vendor agrees to
indemnify the Purchaser against any costs arising in connection with such claim or the
exercise of such rights, be carried out by the Vendor, provided always that where any party
to such proceedings (other than the Vendor) is at the time such proceedings are commenced
or are being pursued by a material customer or supplier of the Business, the Vendor will
consult with the Purchaser in relation to the conduct of the proceedings. The Purchaser
shall take such action and give such information and assistance in connection with the
affairs of the Business as the Vendor may reasonably request to assist the Vendor to avoid,
dispute, resist, mitigate, compromise, defend or appeal against any claim in respect
thereof or to exercise such rights.

 

Page 14 of 30

 

	19.	 	RESTRICTIONS

	 	19.1.	 	The Vendor hereby undertakes with the Purchaser that he will not:

	 	19.1.1.	 	for a period of 12 months from the Completion Date be directly or indirectly
interested or concerned in or assist in carrying on any business undertaking company or
firm carrying on any business within the United Kingdom which is directly competitive
either with the Business or the Purchaser’s infectious disease business (whose
products are listed in Appendix 1) as they are carried on at the date hereof PROVIDED
that nothing herein contained shall prevent the Vendor from being the holder of or from
being beneficially interested in any class of securities in any company if such class
of securities is listed or dealt in on a recognised Stock Exchange or the Unlisted
Securities Market of the Stock Exchange where the Vendor neither
holds nor is beneficially interested in more than a total of five per centum of any
single class of the securities in that company

	 	19.1.2.	 	for a period of 12 months from Completion either on his own account or on behalf of
any other person firm or company solicit orders or contracts for goods of similar type
to those being provided by the Business or the Purchaser’s infectious disease business
(whose products are listed in Appendix 1) at the date hereof from any person firm or
company who or which is at the Completion Date or has been at any time within the
twelve months prior to the Completion Date a customer of or supplier to the Business

	 	19.1.3.	 	save as required to do so by law at any time hereafter make disclosure of or divulge
to any third party any information of a secret or confidential nature relating to the
Business or use such information for his own benefit or

	 	19.1.4.	 	at any time hereafter in relation to a trade or business competitive or likely to be
competitive with that the Business acquired by the Purchaser at the Completion Date use
or allow to be used the Business Name.

 

Page 15 of 30

 

	 	19.2.	 	The restrictions contained in clause 19.1 have been carefully considered by the Vendor
who accepts that they are reasonable and necessary for the proper protection of the
Goodwill accordingly the benefit thereof may be assigned by the Purchaser and its
successors in the Business but in the event that any of the restrictions shall be found to
be unenforceable for whatever reason but would be valid if some part thereof were deleted
or the period or area of application reduced such restriction shall apply with such
modification as may be necessary to make it valid and effective and the remaining
restrictions shall continue to bind the Vendor.

	 	19.3.	 	Nothing in this clause 19 shall prevent the Vendor from continuing to sell,
distribute, market and otherwise deal with the Excluded Products set out in Schedule 5 and
such other products that are not competitive with the Business at the date of Completion

MISCELLANEOUS MATTERS IN RESPECT OF THE SALE OF THE BUSINESS

	20.	 	The Vendor will carry on the Business in a reasonable manner up to Completion and knowingly
do nothing which shall injure the goodwill thereof

	 
	21.	 	All books of account relating to the Business shall remain the property of the Vendor and
retained by him but shall be made available for inspection by the Purchaser or his accountants
at reasonable times upon request during the period between the date hereof and the date twelve
months after the date of Completion

	22.	 	INTERPRETATION GOVERNING LAW AND OTHER MISCELLANEOUS PROVISIONS

	 	22.1.	 	No variations to this Agreement shall be effective unless in writing and signed by
each party hereto

	 	22.2.	 	This Agreement supersedes any previous agreement between the parties in relation to
the matters dealt with herein and represents the entire understanding of the parties in
relation thereto

 

Page 16 of 30

 

	 	22.3.	 	This Agreement shall be binding on the Vendor and the Purchaser their successors in
title and assigns and personal representatives (as the case may be)

	 	22.4.	 	This agreement shall be governed by English Law and the parties agree to submit to the
exclusive jurisdiction of the English courts

	 	22.4.1.	 	Any notice or other document to be given or sent hereunder shall be in writing and
may be delivered personally or sent by first class registered post to the party to be
served at that party’s address appearing in this Agreement or such other address as
that party shall notify in writing to the other. Any such notice or document shall
be deemed to have been served:

	 	22.4.1.1.	 	if delivered at the time of delivery

	 
	 	22.4.1.2.	 	if posted at the expiration of forty-eight hours after the envelope containing
the same shall have been put into the post

	 	22.4.2.	 	In proving such service it shall be sufficient to prove (as the case may be) that
delivery was made or that the envelope containing such notice or document was properly
addressed and posted as a prepaid first-class registered letter

AS WITNESS the hands of the parties hereto the day and year first above written

 

Page 17 of 30

 

THE SCHEDULE hereinbefore referred to

SCHEDULE 1

The Employees

Paul Armitage

 

Page 18 of 30

 

SCHEDULE 2

Fixtures & Fittings

Depreciated value as at 28-9-2007

	 	 	 	 	 
	• 1. Walk-in cold room
	 	£	1680.00	 
	 
	 	 	 	 
	• 2. Cold room temperature recording chart
	 	included in 1
	 
	 	 	 	 
	• 3. Cold room racking and shelving
	 	£	345.00	 
	 
	 	 	 	 
	• 4. Steel cupboards
	 	£	1.00	 
	 
	 	 	 	 
	• 5. Literature storage units x 20
	 	£	1.00	 
	 
	 	 	 	 
	• 6. Binding machine
	 	£	1.00	 
	 
	 	 	 	 
	• 7. Safety step ladder
	 	£	105.00	 

 

Page 19 of 30

 

SCHEDULE 3

Field Instrumentation

Amortised Value

	 	 	 	 	 
	 
	 	 	28/9/2007	 
	 
	 	 	 	 
	Beeblot Robotics Western Blot Processor No1
	 	£	2955.00	 
	 
	 	 	 	 
	Beeblot Robotics Western Blot Processor No2
	 	£	4566.00	 
	 
	 	 	 	 
	P800 Microplate Reader and Printer
	 	£	1738.00	 

 

Page 20 of 30

 

SCHEDULE 4

Purchase Price and Payment

The purchase price shall be computed and paid as follows:

1. For Goodwill,

1.1 1.6 times the sales of the Business for the year ended 31 December 2006 being the sum of
£648,608 (being 405,380 x 1.6) to be paid upon Completion

1.2 5% of the sales of the Business for the period 1 April 2007 to 30 September 2007, provided
the sales for the period exceed the run rate for 2006. For illustrative purposes, if sales for
the 12 month period ended 31 December 2006 are £390,000, sales must equal or exceed £195,000 for
6 months to 30 September 2007 for the 5% to be paid, and in such circumstances an amount of
£9,750 would be payable (being 5% of £195,000). In the event that sales for the 6 month period
ending 30 September 2007 are £220,000 an amount of £11,000 would be payable (being 5% of
£220,000). Any amount due under this clause 1.2 shall be paid within 30 working days of
completion.

1.3 In the event that the Vendors are entitled to receive the payment due pursuant to paragraph
1.2 above a further payment of 25% of the incremental sales of the Business during the 6 month
period to 30 September 2007. This 25% incremental purchase consideration will only be payable in
respect of new sales to existing customers and sales to new customers during the period. For
example, if sales for the 6 month period to 30 September 2007 amount to £220,000, an incremental
purchase consideration of £6,250 will be paid being 25% of the excess over £195,000 Any amount
due under this clause 1.3 shall be paid within 30 working days of completion.

 

Page 21 of 30

 

2. In calculating the amounts due under 1.2 and 1.3 above, the Business shall be conducted in
accordance with normal terms and conditions. Specifically, orders which would otherwise be due
for delivery in the period after 30 September 2007 shall not be delivered in advance of 30
September 2007; extended credit terms shall not be offered; and goods shall not be sold on a sale and
return basis.

3. All useable stocks of the Business shall be acquired at cost. Any amount due under this
clause shall be paid within 30 working days of completion. Cost shall mean the current Sterilab
transfer price from Trinity Biotech Manufacturing Limited in Euro converted to Sterling at the
Travillex/Reush exchange rate for Euro at completion. Usable stocks means that the products can
be sold in the market to existing customers off existing run rates prior to expiration.

4. For Fixtures and Fittings and Field Instrumentation, the price shall be based on depreciated
or amortised value as listed in Schedule 2 and 3 respectively. Amounts due under this clause
shall be paid within 30 working days of completion.

 

Page 22 of 30

 

SCHEDULE 5

EXCLUDED PRODUCTS

	a)	 	Diagnostics for the following analytes: HIV, HTLV, Hepatitis markers, Malaria

	b)	 	Rapid tests other than for analtyes for which Trinity Biotech has CE marked rapid tests
as at the Completion Date

	c)	 	Nucleic acid, PCR, molecular tests other than for analytes for which Trinity Biotech
has CE marked Nucleic acid, PCR, molecular tests as at the Completion Date

	d)	 	Bion and Apette products listed on pages 22 and 23 of the Vendor’s 2007 catalogue

 

Page 23 of 30

 

SCHEDULE 6

Warranties

	A 	 	GENERAL

	 	A1	 	Vendor’s other interests

The Vendor does not have any interest directly or indirectly in any business which is or is
likely to be or become competitive with the Business

	 	A2	 	Ownership of assets

	 	(1)	 	The Vendor owns the Assets and has not parted with the ownership possession or
control of or disposed or agreed to dispose of or granted or agreed to grant any option
or right of pre-emption in respect of or offered for sale its estate or interest in any
of the Assets

	 	(2)	 	None of the Assets are subject to any encumbrance (including without limitation
any debenture mortgage charge lien deposit by way of security bill of sale lease
hire-purchase credit-sale or other agreement for payment on deferred terms option or
right of pre-emption) or any agreement or commitment to give or create any of the
foregoing

	 	A3	 	Vulnerable antecedent transactions

The Vendor has not at any relevant time been party to a transaction pursuant to or as a
result of which any of the Assets are liable to be transferred or re-transferred to another
person or which gives or may give rise to a right of compensation or other payment in favour
of another person under the law of any relevant jurisdiction or country

	 	A4	 	Litigation and defaults

	 	(1)	 	The Vendor is not engaged in any litigation or arbitration proceedings
affecting the Business or the Assets as plaintiff or defendant except as claimant for
collection of debts and there are no such proceedings (as far as the Vendor is aware)
pending or threatened by or against the Vendor

	 	(2)	 	The Vendor does not know of anything which is likely to give rise to any
litigation or arbitration proceedings by or against the Vendor affecting the Assets

 

Page 24 of 30

 

	 	(3)	 	There has not been any default by the Vendor under any agreement or arrangement
to which it is a party in relation to the Assets or the Business and as far as the
Vendor is aware no threat or claim of any such default has been made and is outstanding

	 	(4)	 	The Business is not the subject of any investigation inquiry or enforcement
proceedings or process by any governmental administrative or regulatory body in
relation to the Assets or the Business nor is the Vendor aware of any thing which is
likely to give rise to any such investigation inquiry proceedings or process

	 	A5	 	Insolvency

	 	(1)	 	No receiver or administrative receiver has been appointed in respect of the
whole or any part of the assets or undertaking of the Vendor (including any of the
Assets)

	 	(2)	 	The Vendor has not stopped or suspended payment of its debts become unable to
pay its debts or otherwise become insolvent in any relevant jurisdiction

	 	(3)	 	No unsatisfied judgement order or award is outstanding against the Vendor in
relation to the Business and no written demand under s.123(1)(a) of the Insolvency Act
has been made against the Vendor and no distress or execution has been levied on or
other process commenced against any part of the Assets

	 	A6	 	Capacity and consequences of sale

	 	(1)	 	The Vendor has the requisite power and authority to enter into and perform this
agreement

	 
	 	(2)	 	Compliance with the terms of this agreement does not and will not:

	 	(a)	 	conflict with or constitute a default under any provision of:

	 	(i)	 	any agreement or instrument to which the Vendor is a party; or

	 
	 	(ii)	 	any loan to or mortgage created by the Vendor or any lien lease
order judgment award injunction decree ordinance or regulation or any other
restriction of any kind or character to which any of the Assets is subject or by
which the Vendor is bound; or

 

Page 25 of 30

 

	 	(b)	 	relieve any other party to a contract with the Vendor in relation to
the Business of its obligations or enable it to vary or terminate its obligations
under that contract; or

	 
	 	(c)	 	result in the creation or imposition of any lien charge or encumbrance
of any nature on any of the Assets

	B	 	COMMERCIAL AND FINANCIAL

	 	B1	 	Suppliers and customers

To the best of the knowledge information and belief of the Vendor

	 	(1)	 	no supplier of the Business has ceased or will cease supplying the Business or
has reduced or will reduce its supplies to the Business; and

	 	(2)	 	no customer of the Business has in the last 12 months terminated or is
intending to terminate any contract relating to the Business or to withdraw or reduce
its custom with it after Completion or as a result of the proposed acquisition of the
Business by the Purchaser

	 	B2	 	Contracts and financials

	 	(1)	 	The Purchaser (as successor to the Vendor) will not be required after the date
of this agreement to undertake any work or supply any goods or services relating to the
Business except on normal commercial terms under a contract entered into on or before
the date of this agreement

	 	(2)	 	No offer tender or the like in respect of the Business which is capable of
being converted into an obligation of the Vendor by an acceptance or other act on some
other person is outstanding except in the ordinary course of the Business

	 	B3	 	Material contracts

The Vendor is not a party to any contract arrangement or obligation relating to the Business
which whether by reason of its nature term scope price or otherwise is or is likely to be of
material importance to the Business or the profitability of the Business or which:

	 	(1)	 	is not in the ordinary course of trading of the Business; or

	 
	 	(2)	 	is incapable of performance in accordance with its terms within six months of
the date on which it was entered into or undertaken; or

 

Page 26 of 30

 

	 	(3)	 	is expected to result in a loss on completion of performance; or

	 
	 	(4)	 	is of an onerous nature or cannot be fulfilled or performed on time and without
undue or unusual expenditure of money and effort; or

	 	B4	 	Agencies etc

The Vendor is not in relation to the Business a party to:

	 	(1)	 	save for the Distribution Agreement any agency distributorship marketing
purchasing manufacturing or licensing agreement or arrangement; or

	 	(2)	 	any agreement or arrangement which restricts its freedom to carry on the whole
or any part of the Business in any part of the world in such manner as it thinks fit

	C	 	ASSETS

	 	C1	 	The Vendor has good and marketable title to all of the Assets and the Vendor owns
absolutely all such Assets free from and not subject to any agreement or commitment to give
or create any mortgage charge lien option bill of sale or any other encumbrance or claim of
any kind and in particular none of the Stocks are subject to any reservation of title in
favour of any third party or purchased generally on terms that ownership does not pass to
the relevant Seller until full payment is made by it to the supplier

	 	C2	 	The Stocks have been fully paid for by the Vendor and are of satisfactory quality
readily realisable and saleable at normal selling prices in the ordinary course of the
Business and will have a minimum remaining shelf life of 3 months from the Completion Date

	 
	 	C3	 	The Stocks are sufficient for the normal requirements of the Business

 

Page 27 of 30

 

	D	 	POWERS OF ATTORNEY

	 
	 	 	There are in force no powers of attorney given by the Vendor in connection with the conduct of
the Business. No person as agent or otherwise is entitled or authorised to enter into any
contract commitment or obligation on behalf of the Business which is not in the ordinary course
of such Business

	E	 	BUSINESS NAMES

	 
	 	 	The Vendor uses no name for any purpose in
connection with the Business other than the
Business Name.

	F	 	MATERIAL INFORMATION

To the best of the Vendor’s knowledge information and belief there is

	 	F1	 	No fact or matter material to the value of the Assets or materially affecting the
aggregate value of such Assets; and

	 	F2	 	no fact or matter materially affecting the trading of the Business which has not been
disclosed to the Purchaser and the disclosure of which might reasonably be expected
materially to affect the willingness of the Purchaser to purchase such Assets at the
aggregate price or the terms on which the purchase is made

 

Page 28 of 30

 

SIGNED as a Deed by Kenneth Alfred Frizelle in
the presence of

Signature of Witness:

Name:

Address:

Occupation

SIGNED as a Deed by Trevor Frizelle in the
presence of

Signature of Witness:

Name:

Address:

Occupation:

SIGNED as a Deed by Kevin Frizelle in the
presence of

Signature of Witness:

Name:

Address:

Occupation:

 

Page 29 of 30

 

SIGNED as a Deed by James Frizelle in the
presence of

Signature of Witness:

Name:

Address:

Occupation:

SIGNED as a Deed by Dianne Margaret Frizelle
in the presence of

Signature of Witness:

Name:

Address:

Occupation:

EXECUTED as a Deed by Trinity Biotech (UK
Sales) Limited acting by its Director and
Secretary or two Directors

Director:

Director/Secretary:

 

Page 30 of 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]